Soo Aleman

Publikationer
Forskningsbidrag
CV
Populärvetenskap och samverkan

Artiklar

Article: JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY. 2024;:S0091-6749(24)01125-4
Inborn errors of immunity are associated with increased COVID-19-related hospitalization and intensive care compared to the general population.
Lindahl H; Kahn F; Nilsdotter-Augustinsson Å; Fredrikson M; Hedberg P; Möller IK; Hansson L; Blixt L; Sylvan SE; Österborg A; Aleman S; Carlander C; Nyström S; Bergman P
Article: EBIOMEDICINE. 2024;109:105385
Real-world assessment of immunogenicity in immunocompromised individuals following SARS-CoV-2 mRNA vaccination: a two-year follow-up of the prospective clinical trial COVAXID
Chen P; Bergman P; Blennow O; Hansson L; Mielke S; Nowak P; Gao Y; Soderdahl G; Osterborg A; Smith CIE; Vesterbacka J; Wullimann D; Cuapio A; Akber M; Bogdanovic G; Muschiol S; Aberg M; Lore K; Chen MS; Ljungman P; Buggert M; Aleman S; Ljunggren H-G
Article: JOURNAL OF HEPATOLOGY. 2024;81(4):621-629
Bulevirtide monotherapy in patients with chronic HDV : Efficacy and safety results through week 96 from a phase III randomized trial
Wedemeyer H; Aleman S; Brunetto M; Blank A; Andreone P; Bogomolov P; Chulanov V; Mamonova N; Geyvandova N; Morozov V; Sagalova O; Stepanova T; Berger A; Ciesek S; Manuilov D; Mercier R-C; Da BL; Chee GM; Li M; Flaherty JF; Lau AH; Osinusi A; Wiesch JSZ; Cornberg M; Zeuzem S; Lampertico P
Article: INFECTIOUS DISEASES. 2024;:1-13
Long-term risk of HCC in a DAA-treated national hepatitis C cohort, and a proposed risk score
Lybeck C; Bruce D; Szulkin R; Montgomery S; Aleman S; Duberg A-S
Article: INFECTIOUS DISEASES. 2024;:1-14
Risk of COVID-19 hospitalisation by HIV-status and SARS-CoV-2 vaccination status during pre- and post-Omicron era in a national register-based cohort study in Sweden
Moller IK; Hedberg P; Wagner P; Lindahl H; Nystrom S; Blixt L; Sylvan SE; Nilsdotter-Augustinsson A; Osterborg A; Fredrikson M; Hansson L; Kahn F; Sparen P; Gisslen M; Naucler P; Bergman P; Aleman S; Carlander C
Journal article: JOURNAL OF DENTAL SCIENCES. 2024
The salivary microbiome and oral health status in HBeAg-negative chronic hepatitis B
Lu L; Yan L; Sohrabi A; Lindahl K; Cederberg S; Wang R; Ye W; Aleman S; Chen MS
Article: JOURNAL OF INFECTIOUS DISEASES. 2024;230(2):e318-e326
Type I Interferon Autoantibodies Correlate With Cellular Immune Alterations in Severe COVID-19
Strunz B; Maucourant C; Mehta A; Wan H; Du L; Sun D; Chen P; Nordlander A; Gao Y; Cornillet M; Bister J; Kvedaraite E; Christ W; Klingstrom J; Geanon D; Parke A; Ekwall-Larson A; Rivino L; MacAry PA; Aleman S; Buggert M; Ljunggren H-G; Pan-Hammarstrom Q; Lund-Johansen F; Stralin K; Bjorkstrom NK
Article: SCIENTIFIC REPORTS. 2024;14(1):17820
Exploring the interplay between antiretroviral therapy and the gut-oral microbiome axis in people living with HIV
Narayanan A; Kieri O; Vesterbacka J; Manoharan L; Chen P; Ghorbani M; Ljunggren H-G; Chen MS; Aleman S; Soennerborg A; Ray S; Nowak P
Article: ALIMENTARY PHARMACOLOGY AND THERAPEUTICS. 2024;60(4):434-445
Clinical trial: An open-label, randomised trial of different re-start strategies after treatment withdrawal in HBeAg negative chronic hepatitis B
Johannessen A; Reikvam DH; Aleman S; Berhe N; Weis N; Desalegn H; Stenstad T; Heggelund L; Samuelsen E; Karlsen LN; Lindahl K; Pettersen FO; Iversen J; Kleppa E; Bollerup S; Winckelmann AA; Brugger-Synnes P; Simonsen HE; Svendsen J; Kran A-MB; Holmberg M; Olsen IC; Rueegg CS; Dalgard O
Article: JOURNAL OF HEPATOLOGY. 2024;:S0168-8278(24)02337-7
Patient-reported outcomes in chronic hepatitis delta: An exploratory analysis of the phase III MYR301 trial of bulevirtide.
Buti M; Wedemeyer H; Aleman S; Chulanov V; Morozov V; Sagalova O; Stepanova T; Gish RG; Lloyd A; Kaushik AM; Suri V; Manuilov D; Osinusi AO; Flaherty JF; Lampertico P
Article: LIVER INTERNATIONAL. 2024;44(7):1689-1699
Liver stiffness predicts progression to liver-related events in patients with chronic liver disease - A cohort study of 14 414 patients
Hegmar H; Wester A; Aleman S; Backman J; Degerman E; Ekvall H; Lund K; Lundgren A; Nasr P; Shahnavaz A; Vessby J; Westin J; Onnerhag K; Hagstrom H
Article: INTERNATIONAL JOURNAL OF DRUG POLICY. 2024;128:104433
Changes in hepatitis C virus prevalence and incidence among people who inject drugs in the direct acting antiviral era
Gahrton C; Naver G; Warnqvist A; Dalgard O; Aleman S; Kaberg M
Journal article: JOURNAL OF HEPATOLOGY. 2024;80:s758
TOP-400 Impact of bulevirtide given with or without nucleos (t)ide analogues on 48-week virologic outcomes in patients with chronic hepatitis delta virus infection
Lampertico P; Brunetto M; Buti M; Aleman S; Bogomolov P; Chulanov V; Mamonova N; Morozov V; Sagalova O; Stepanova T; Flaherty JF; Li M; Manuilov D; Da BL; Mercier R-C; Chee GM; Cornberg M; Wedemeyer H; Asselah T
Journal article: JOURNAL OF HEPATOLOGY. 2024;80:s794
WED-392 Improvement in liver histology is observed in most patients with chronic hepatitis delta after 48weeks of bulevirtide monotherapy
Lampertico P; Aleman S; Bogomolov P; Stepanova T; Cornberg M; Ciesek S; Berger A; Manuilov D; Li M; Lau AH; Da BL; Chee GM; Brunetto M; Zeuzem S; Wedemeyer H
Journal article: JOURNAL OF HEPATOLOGY. 2024;80:s92
LBP-029 Efficacy and safety of 144 weeks of bulevirtide 2 mg or 10 mg monotherapy from the ongoing phase 3 study, MYR301
Lampertico P; Aleman S; Brunetto M; Blank A; Andreone P; Bogomolov P; Chulanov V; Mamonova N; Geyvandova N; Morozov V; Sagalova O; Stepanova T; Chee GM; Manuilov D; Li M; Tseng S; Lau A; Osinusi A; Wiesch JSZ; Cornberg M; Zeuzem S; Wedemeyer H
Journal article: JOURNAL OF HEPATOLOGY. 2024;80:s100
LBP-044 Robust reduction of HBsAg and HDV RNA levels with low risk for ALT elevations in JNJ-73763989 treated patients with chronic hepatitis D (CHD) and baseline HBsAg levels below 10, 000 IU/ml: part 2 of the REEF-D study
Wedemeyer H; Lampertico P; Gane EJ; Agarwal K; Tabak F; Akarca U; Aleman S; Buti M; Sprinzl K; Donohue K; Jerzorwski J; Kakuda T; Verbinnen T; Bakala A; Lenz O; Biermer M
Journal article: JOURNAL OF HEPATOLOGY. 2024;80:s795
WED-394 Hepatic flares after nucleos (t)ide analogue cessation in HBeAg-negative hepatitis B: results from the Nuc-Stop study
Holmberg M; Dalgard O; Aleman S; Berhe N; Dessalegn H; Weis N; Heggelund L; Karlsen LN; Brugger-Synnes P; Simonsen HE; Reikvam DH; Johannessen A
Journal article: JOURNAL OF HEPATOLOGY. 2024;80:s759
TOP-416-YI High frequency of liver cirrhosis in european patients with hepatitis D: first data froma large multicentre study (D-SOLVE and HDV-1000 consortia)
Wranke A; Kamal H; Cargill Z; Radu M; Degasperi E; Lindahl K; Dörge P; Kahlhöfer J; Agarwal K; Lampertico P; Caruntu FA; Wedemeyer H; Aleman S; Carey I; Sandmann L
Journal article: GASTROENTEROLOGY. 2024;166(5):s-1603-s-1604
Sa1626 HIGH RATES OF ADHERENCE TO BULEVIRTIDE MONOTHERAPY FOR CHRONIC HEPATITIS DELTA THROUGH 96 WEEKS: RESULTS FROM AN INTERIM ANALYSIS OF THE PHASE 3 STUDY MYR301
Aleman S; Wedemeyer H; Brunetto MR; Blank A; Andreone P; Bogomolov P; Chulanov V; Mamonova N; Geyvandova N; Morozov V; Sagalova O; Stepanova TV; Da B; Manuilov D; Chee G; Li M; Lau AH; Wiesch JSZ; Cornberg M; Zeuzem S; Lampertico P
Journal article: GASTROENTEROLOGY. 2024;166(5):s-1600
Sa1618 EFFICACY AND SAFETY AT 96 WEEKS OF BULEVIRTIDE 2 MG OR 10 MG MONOTHERAPY FOR CHRONIC HEPATITIS DELTA: RESULTS FROM AN INTERIM ANALYSIS OF A PHASE 3 RANDOMIZED STUDY
Wedemeyer H; Aleman S; Brunetto MR; Blank A; Andreone P; Bogomolov P; Chulanov V; Mamonova N; Geyvandova N; Morozov V; Sagalova O; Stepanova TV; Manuilov D; Mercier R-C; An Q; Flaherty JF; Osinusi A; Lau AH; Wiesch JSZ; Cornberg M; Zeuzem S; Lampertico P
Article: ALIMENTARY PHARMACOLOGY AND THERAPEUTICS. 2024;59(6):752-761
Liver stiffness measurement as a noninvasive method for the diagnosis of liver cirrhosis in patients with chronic hepatitis D virus infection
Sandmann L; Degasperi E; Port K; Aleman S; Wallin JJ; Manuilov D; Da BL; Cornberg M; Lampertico P; Maasoumy B; Wedemeyer H; Deterding K
Article: CELL HOST AND MICROBE. 2024;32(2):156-161.e3
Memory T cells effectively recognize the SARS-CoV-2 hypermutated BA.2.86 variant
Muller TR; Gao Y; Wu J; Ribeiro O; Chen P; Bergman P; Blennow O; Hansson L; Mielke S; Nowak P; Vesterbacka J; Akber M; Soderdahl G; Smith CIE; Lore K; Chen MS; Ljungman P; Ingelman-Sundberg HM; Ljunggren H-G; Osterborg A; Sette A; Grifoni A; Aleman S; Buggert M
Article: MOLECULAR THERAPY. 2024;32(2):540-555
Distinct roles of vaccine-induced SARS-CoV-2-specific neutralizing antibodies and T cells in protection and disease
Yan J; Bangalore CR; Nikouyan N; Appelberg S; Silva DN; Yao H; Pasetto A; Weber F; Weber S; Larsson O; Hoglund U; Bogdanovic G; Grabbe M; Aleman S; Szekely L; Szakos A; Tuvesson O; Gidlund E-K; Cadossi M; Salati S; Tegel H; Hober S; Frelin L; Mirazimi A; Ahlen G; Sallberg M
Article: JOURNAL OF HEPATOLOGY. 2024;80(2):232-242
Adjusted estimate of the prevalence of hepatitis delta virus in 25 countries and territories.
Polaris Observatory Collaborators
Article: JOURNAL OF IMMUNOLOGY. 2024;212(3):389-396
Dynamic MAIT Cell Recovery after Severe COVID-19 Is Transient with Signs of Heterogeneous Functional Anomalies
Kammann T; Gorin J-B; Parrot T; Gao Y; Ponzetta A; Emgard J; Maleki KT; Sekine T; Rivera-Ballesteros O; Gredmark-Russ S; Rooyackers O; Skagerberg M; Eriksson LI; Norrby-Teglund A; Mak JYW; Fairlie DP; Bjorkstrom NK; Klingstrom J; Ljunggren H-G; Aleman S; Buggert M; Stralin K; Sandberg JK
Article: LIVER INTERNATIONAL. 2024;44(1):228-240
The cascade of care for patients with chronic hepatitis delta in Southern Stockholm, Sweden for the past 30 years
Kamal H; Lindahl K; Ingre M; Gahrton C; Karkkonen K; Nowak P; Vesterbacka J; Stal P; Wedemeyer H; Duberg A-S; Aleman S
Article: NPJ BIOFILMS AND MICROBIOMES. 2023;9(1):104
Impact of the gut microbiome on immunological responses to COVID-19 vaccination in healthy controls and people living with HIV
Ray S; Narayanan A; Vesterbacka J; Blennow O; Chen P; Gao Y; Gabarrini G; Ljunggren H-G; Buggert M; Manoharan L; Chen MS; Aleman S; Sonnerborg A; Nowak P
Article: SCIENCE IMMUNOLOGY. 2023;8(90):eadh0687
SARS-CoV-2 vaccination enhances the effector qualities of spike-specific T cells induced by COVID-19
Cai C; Gao Y; Adamo S; Rivera-Ballesteros O; Hansson L; Osterborg A; Bergman P; Sandberg JK; Ljunggren H-G; Bjorkstrom NK; Stralin K; Llewellyn-Lacey S; Price DA; Qin C; Grifoni A; Weiskopf D; Wherry EJ; Sette A; Aleman S; Buggert M
Article: HEPATOLOGY COMMUNICATIONS. 2023;7(12):e0334
Age-specific and sex-specific risks for HCC in African-born persons with chronic hepatitis B without cirrhosis
Kamal H; Ingre M; Stal P; Westman G; Bruce D; Wedemeyer H; Duberg A-S; Aleman S
Journal article: AMERICAN JOURNAL OF GASTROENTEROLOGY. 2023;118(10S):s1214
S1617 Elevations in Total Serum Bile Acids During Bulevirtide Treatment Show No Association With Adverse Events of Interest in Patients With Chronic Hepatitis Delta: An Integrated Safety Analysis of 48-Week Data
Lampertico P; Aleman S; Asselah T; Streinu-Cercel A; Bogomolov P; Morozov V; Stepanova T; Lazar S; Bacic A; Manuilov D; Mercier R-C; Flaherty JF; Suri V; Ye L; Tseng S; Christian-Cox F; Brunetto M; Wedemeyer H
Article: THE LANCET GASTROENTEROLOGY AND HEPATOLOGY. 2023;8(10):879-907
Global prevalence, cascade of care, and prophylaxis coverage of hepatitis B in 2022: a modelling study
Razavi-Shearer DM; Gamkrelidze I; Pan CQ; Jia J; Berg T; Gray RT; Lim Y-S; Chen C-J; Ocama P; Desalegn H; Abbas Z; Abdallah AR; Aghemo A; Ahmadbekova S; Ahn SH; Aho I; Akarca US; Al Masri NM; Alalwan AM; Alavian SM; Al-Busafi SA; Aleman S; Alfaleh FZ; Alghamdi AS; Al-Hamoudi WK; Aljumah AA; Al-Naamani K; Al-Rifai A; AlSerkal YM; Altraif IH; Amarsanaa J; Anderson M; Andersson MI; Armstrong P; Asselah T; Athanasakis K; Baatarkhuu O; Ben-Ari Z; Bensalem A; Bessone F; Biondi MJ; Bizri ARN; Blach S; Braga WSM; Brandao-Mello CE; Brosgart CL; Brown KA; Jr RSB; Bruggmann P; Brunetto MR; Buti M; Cabezas J; Casanovas T; Chae C; Chan HLY; Cheinquer H; Chen P-J; Cheng KJG; Cheon M-E; Chien C-H; Choudhuri G; Christensen PB; Chuang W-L; Chulanov V; Garza LEC; Coffin CS; Contreras FA; Coppola N; Cornberg M; Cowie B; Cramp ME; Craxi A; Crespo J; Cui F; Cunningham CW; Dalgard O; De Knegt RJ; De Ledinghen V; Dore GJ; Drazilova S; Duberg A-S; Egeonu S; Elbadri M; El-Kassas M; El-Sayed MH; Estes C; Etzion O; Farag E; Ferradini L; Ferreira PRA; Flisiak R; Forns X; Frankova S; Fung J; Gane EJ; Garcia V; Garcia-Samaniego J; Gemilyan M; Genov J; Gheorghe LS; Gholam PM; Gish RG; Goleij P; Gottfredsson M; Grebely J; Gschwantler M; Guingane NA; Hajarizadeh B; Hamid SS; Hamoudi W; Harris AM; Hasan I; Hatzakis A; Hellard ME; Hercun J; Hernandez J; Hockickova I; Hsu Y-C; Hu C-C; Husa P; Janicko M; Janjua N; Jarcuska P; Jaroszewicz J; Jelev D; Jeruma A; Johannessen A; Kaberg M; Kaita KDE; Kaliaskarova KS; Kao J-H; Kelly-Hanku A; Khamis F; Khan AG; Kheir OO; Khoudri I; Kondili LA; Konysbekova A; Kristian P; Kwon JA; Lagging M; Laleman W; Lampertico P; Lavanchy D; Lazaro P; Lazarus JV; Lee AU; Lee M-H; Liakina V; Luksic B; Malekzadeh R; Malu AO; Marinho RT; Mendes-Correa MC; Merat S; Meshesha BR; Midgard H; Mohamed R; Mokhbat JE; Mooneyhan E; Moreno C; Mortgat L; Mullhaupt B; Musabaev E; Muyldermans G; Naveira MCM; Negro F; Nersesov AV; Van TTN; Ning Q; Njouom R; Ntagirabiri R; Nurmatov ZS; Oguche S; Omuemu CE; Ong JP; Opare-Sem OK; Ormeci N; Orrego M; Osiowy C; Papatheodoridis GV; Peck-Radosavljevic M; Pessoa MG; Pham TND; Phillips RO; Pimenov N; Pincay-Rodriguez LDR; Plaseska-Karanfilska D; Pop C; Poustchi H; Prabdial-Sing NN; Qureshi H; Ramji A; Rautiainen H; Razavi-Shearer K; Remak WM; Ribeiro S; Ridruejo E; Rios-Hincapie CY; Robalino MC; Roberts LR; Roberts SK; Rodriguez M; Roulot D; Rwegasha J; Ryder SD; Sadirova S; Saeed U; Safadi R; Sagalova O; Said SS; Salupere R; Sanai FM; Sanchez-Avila JF; Saraswat VA; Sargsyants N; Sarrazin C; Sarybayeva G; Schreter I; Seguin-Devaux C; Seto W-K; Shah SR; Sharara AI; Sheikh M; Shouval D; Sievert W; Simojoki K; Simonova MY; Sinn DH; Sonderup MW; Sonneveld MJ; Spearman CW; Sperl J; Stauber RE; Stedman CAM; Sypsa V; Tacke F; Tan S-S; Tanaka J; Tergast TL; Terrault NA; Thompson AJ; Thompson PJ; Tolmane I; Tomasiewicz K; Tsang T-Y; Uzochukwu BSC; Van Welzen B; Vanwolleghem T; Vince A; Voeller AS; Waheed Y; Waked I; Wallace J; Wang C; Weis N; Wong GL-H; Wong VW-S; Wu J-C; Yaghi CG; Yesmembetov K; Yip TC-F; Yosry A; Yu M-L; Yuen M-F; Yurdaydin C; Zeuzem S; Zuckerman E; Razavi HA
Article: JOURNAL OF HEPATOLOGY. 2023;79(3):657-665
No virologic resistance to bulevirtide monotherapy detected in patients through 24 weeks treatment in phase II and III clinical trials for chronic hepatitis delta
Hollnberger J; Liu Y; Xu S; Chang S; Martin R; Manhas S; Aeschbacher T; Han B; Yazdi T; May L; Han D; Shornikov A; Flaherty J; Manuilov D; Suri V; Asselah T; Lampertico P; Wedemeyer H; Aleman S; Richards C; Mateo R; Maiorova E; Cihlar T; Mo H; Urban S
Journal article: JHEP REPORTS. 2023;5(9):100818
Hepatitis D virus infection: Pathophysiology, epidemiology and treatment. Report from the first international delta cure meeting 2022
Lampertico P; Degasperi E; Sandmann L; Wedemeyer H
Article: JOURNAL OF CLINICAL IMMUNOLOGY. 2023;43(6):1075-1082
SARS-CoV-2 Antibodies in Commercial Immunoglobulin Products Show Markedly Reduced Cross-reactivities Against Omicron Variants
Lindahl H; Chen P; Aberg M; Ljunggren H-G; Buggert M; Aleman S; Smith CIE; Bergman P
Article: JOURNAL OF HEPATOLOGY. 2023;79(2):576-580
Hepatitis D double reflex testing of all hepatitis B carriers in low-HBV- and high-HBV/HDV-prevalence countries
Razavi HA; Buti M; Terrault NA; Zeuzem S; Yurdaydin C; Tanaka J; Aghemo A; Akarca US; Al Masri NM; Alalwan AM; Aleman S; Alghamdi AS; Alghamdi S; Al-Hamoudi WK; Aljumah AA; Altraif IH; Asselah T; Ben-Ari Z; Berg T; Biondi MJ; Blach S; Braga WSM; Brandao-Mello CE; Brunetto MR; Cabezas J; Cheinquer H; Chen P-J; Cheon M-E; Chuang W-L; Coffin CS; Coppola N; Craxi A; Crespo J; De Ledinghen V; Duberg A-S; Etzion O; Ferraz MLG; Ferreira PRA; Forns X; Foster GR; Gaeta GB; Gamkrelidze I; Garcia-Samaniego J; Gheorghe LS; Gholam PM; Gish RG; Glenn J; Hercun J; Hsu Y-C; Hu C-C; Huang J-F; Janjua N; Jia J; Kaberg M; Kaita KDE; Kamal H; Kao J-H; Kondili LA; Lagging M; Lazaro P; Lazarus JV; Lee M-H; Lim Y-S; Marotta PJ; Navas M-C; Naveira MCM; Orrego M; Osiowy C; Pan CQ; Pessoa MG; Raimondo G; Ramji A; Razavi-Shearer DM; Razavi-Shearer K; Rios-Hincapie CY; Rodriguez M; Rosenberg WMC; Roulot DM; Ryder SD; Safadi R; Sanai FM; Santantonio TA; Sarrazin C; Shouval D; Tacke F; Tergast TL; Villalobos-Salcedo JM; Voeller AS; Yang H-I; Yu M-L; Zuckerman E
Article: EBIOMEDICINE. 2023;94:104700
Real-world assessment of immunogenicity in immunocompromised individuals following SARS-CoV-2 mRNA vaccination: a one-year follow-up of the prospective clinical trial COVAXID
Chen P; Bergman P; Blennow O; Hansson L; Mielke S; Nowak P; Soderdahl G; oesterborg A; Smith CIE; Vesterbacka J; Wullimann D; Cuapio A; Akber M; Bogdanovic G; Muschiol S; aberg M; Lore K; Chen MS; Buggert M; Ljungman P; Aleman S; Ljunggren H-G
Article: SCIENCE TRANSLATIONAL MEDICINE. 2023;15(704):eadg9452
Additive effects of booster mRNA vaccination and SARS-CoV-2 Omicron infection on T cell immunity across immunocompromised states
Muller TRR; Sekine T; Trubach D; Niessl J; Chen P; Bergman P; Blennow O; Hansson L; Mielke S; Nowak P; Vesterbacka J; Akber M; Olofsson A; Hernandez SPA; Gao Y; Cai C; Soderdahl G; Smith CIE; Osterborg A; Lore K; Sallberg Chen M; Ljungman P; Ljunggren H-G; Karlsson ACC; Saini SK; Aleman S; Buggert M
Article: NEW ENGLAND JOURNAL OF MEDICINE. 2023;389(1):22-32
A Phase 3, Randomized Trial of Bulevirtide in Chronic Hepatitis D
Wedemeyer H; Aleman S; Brunetto MR; Blank A; Andreone P; Bogomolov P; Chulanov V; Mamonova N; Geyvandova N; Morozov V; Sagalova O; Stepanova T; Berger A; Manuilov D; Suri V; An Q; Da B; Flaherty J; Osinusi A; Liu Y; Merle U; Wiesch JSZ; Zeuzem S; Ciesek S; Cornberg M; Lampertico P
Journal article: JOURNAL OF HEPATOLOGY. 2023;78:s57-s58
OS-068 Efficacy and safety at 96 weeks of bulevirtide 2 mg or 10 mg monotherapy for chronic hepatitis D: results from an interim analysis of a phase 3 randomized study
Wedemeyer H; Aleman S; Brunetto M; Blank A; Andreone P; Bogomolov P; Chulanov V; Mamonova N; Geyvandova N; Viacheslav M; Sagalova O; Stepanova T; Manuilov D; Mercier R-C; An Q; Flaherty JF; Osinusi A; Lau A; Wiesch JSZ; Cornberg M; Zeuzem S; Lampertico P
Journal article: JOURNAL OF HEPATOLOGY. 2023;78:s113-s114
LBP-20 Continued treatment of early non-responder or partial virologic responders with bulevirtide monotherapy in patients with chronic hepatitis D through week 96 leads to improvement in virologic and biochemical responses
Lampertico P; Wedemeyer H; Brunetto M; Bogomolov P; Stepanova T; Ciesek S; Berger A; Manuilov D; An Q; Lau A; Da B; Flaherty JF; Mercier R-C; Zeuzem S; Cornberg M; Buti M; Aleman S
Journal article: JOURNAL OF HEPATOLOGY. 2023;78:s1091-s1093
WED-158 Relationship of hepatitis D viral load, ALT levels, and liver stiffness in untreated patients with chronic hepatitis D
Aleman S; Lampertico P; Brunetto M; Bogomolov P; Chulanov V; Mamonova N; Stepanova T; Manuilov D; An Q; Da B; Flaherty JF; Mercier R-C; Lau A; Zeuzem S; Cornberg M; Wedemeyer H
Journal article: JOURNAL OF HEPATOLOGY. 2023;78:s34
OS-030 Treatment with siRNA JNJ-73763989 plus nucleos (t)ide analogue (NA) decreases HBsAg and HDV RNA levels in patients with chronic hepatitis D (CHD): part 1 of the REEF-D study
Wedemeyer H; Gane EJ; Agarwal K; Tabak F; Forns X; Akarca U; Viacheslav M; Aleman S; Buti M; Yilmaz G; Lampertico P; Niewczas J; Jerzorwski J; Kakuda T; Benoot I; Pehlivanov N; Lenz O; Biermer M
Journal article: JOURNAL OF HEPATOLOGY. 2023;78:s10
GS-012 Week 48 results of the phase 3 D-LIVR study, a randomized double-blind, placebo-controlled trial evaluating the safety and efficacy of Lonafarnib-boosted with Ritonavir with or without Peginterferon Alfa in patients with chronic hepatitis delta
Etzion O; Hamid SS; Asselah T; Gherlan GS; Turcanu A; Petrivna T; Weissfeld L; Choong I; Hislop C; Apelian D; Buti M; Gheorghe L; Iliescu EL; Voronkova N; Barsukova N; Aleman S; Feld JJ; Reau NS; Brunetto M; Lampertico P; Heller T; Koh C; Yurdaydin C; Glenn J
Journal article: JOURNAL OF HEPATOLOGY. 2023;78:s1150-s1151
SAT-170 The Nuc-Stop study: an open-label, randomized trial of different re-start strategies after treatment withdrawal in HBeAg negative chronic hepatitis B patients
Johannessen A; Reikvam DH; Aleman S; Berhe N; Weis N; Desalegn H; Stenstad T; Heggelund L; Samuelsen E; Lindahl K; Winckelmann A; Karlsen LN; Brugger-Synnes P; Simonsen HE; Svendsen J; Holmberg M; Dalgard O
Journal article: JOURNAL OF IMMUNOLOGY. 2023;210(1_Supplement):223.13
Booster mRNA vaccination post-SARS-CoV-2 infection enhances functional qualities of T cell immunity
Cai C; Gao Y; Olsson A; Sette A; Wherry EJ; Aleman S; Buggert M
Journal article: GASTROENTEROLOGY. 2023;164(6):s-1367-s-1368
Mo1537 EFFICACY AND SAFETY OF BULEVIRTIDE MONOTHERAPY GIVEN AT 2 MG OR 10 MG DOSE LEVEL ONCE DAILY FOR TREATMENT OF CHRONIC HEPATITIS DELTA: WEEK 48 PRIMARY ENDPOINT RESULTS FROM A PHASE 3 RANDOMIZED, MULTICENTER, PARALLEL-DESIGN STUDY
Wedemeyer H; Aleman S; Brunetto MR; Blank A; Andreone P; Bogomolov P; Chulanov V; Mamonova N; Geyvandova N; Morozov V; Sagalova O; Stepanova TV; Manuilov D; Shah V; Suri V; An Q; Flaherty JF; Osinusi A; Wiesch JSZ; Cornberg M; Zeuzem S; Lampertico P
Journal article: GASTROENTEROLOGY. 2023;164(6):s-1037
Tu1376 RISK OF HEPATITIS B INFECTION IN PEOPLE WITH CELIAC DISEASE; A POPULATION-BASED STUDY
Jossen J; Lebwohl B; Soderling J; Duberg A-S; Aleman S; Sharma R; Hagstrom H; Green PH; Ludvigsson JF
Journal article: JOURNAL OF IMMUNOLOGY. 2023;210(1_Supplement):75.16
Anamnestic expansion of Omicron-reactive CD8 +T cells after booster SARS-CoV-2 mRNA vaccination across different immunocompromised states
Müller TR; Sekine T; Trubach D; Niessl J; Olofsson A; Gao Y; Cai C; Nowak P; Blennow O; Hansson L; Mielke S; Bergman P; Ljunggren H-G; Karlsson AC; Saini SK; Aleman S; Buggert M
Article: PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA. 2023;120(12):e2220320120
Functional SARS-CoV-2 cross-reactive CD4⁺ T cells established in early childhood decline with age
Humbert M; Olofsson A; Wullimann D; Niessl J; Hodcroft EB; Cai C; Gao Y; Sohlberg E; Dyrdak R; Mikaeloff F; Neogi U; Albert J; Malmberg K-J; Lund-Johansen F; Aleman S; Bjorkhem-Bergman L; Jenmalm MC; Ljunggren H-G; Buggert M; Karlsson AC
Journal article: DIGESTIVE AND LIVER DISEASE. 2023;55:s74
Bulevirtide monotherapy is safe and well tolerated in patients with chronic hepatitis D (CHD): An integrated safety analysis of 48-week data
Asselah T; Lampertico P; Aleman S; Bourliere M; Streinu-Cercel A; Bogomolov P; Morozov V; Stepanova T; Lazar S; Suri V; Manuilov D; Mercier RC; Tseng S; Ye L; Flaherty JF; Osinusi A; Brunetto M; Wedemeyer H
Journal article: DIGESTIVE AND LIVER DISEASE. 2023;55:s73
Efficacy of bulevirtide as monotherapy for chronic hepatitis D (CHD): Week 48 results from an integrated analysis
Lampertico P; Aleman S; Blank A; Bogomolov P; Chulanov V; Mamonova N; Morozov V; Sagalova O; Stepanova T; Suri V; Manuilov D; Ye L; Flaherty JF; Osinusi A; Cornberg M; Brunetto M; Wedemeyer H
Journal article: DIGESTIVE AND LIVER DISEASE. 2023;55:s72-s73
Bulevirtide improves health-related quality of life measured by EQ-5D VAS in patients with chronic hepatitis delta: An exploratory analysis of a Phase 3 trial at 48 weeks
Buti M; Wedemeyer H; Aleman S; Chulanov V; Morozov V; Sagalova O; Stepanova T; Gish RG; Lloyd A; Kaushik AM; Suri V; Manuilov D; Osinusi AO; Flaherty J; Pandey S; Singh B; Lampertico P
Article: RESPIRATORY RESEARCH. 2023;24(1):62
Targeted plasma proteomics reveals signatures discriminating COVID-19 from sepsis with pneumonia
Palma Medina LM; Babacic H; Dzidic M; Parke A; Garcia M; Maleki KT; Unge C; Lourda M; Kvedaraite E; Chen P; Muvva JR; Cornillet M; Emgard J; Moll K; Michaelsson J; Flodstrom-Tullberg M; Brighenti S; Buggert M; Mjosberg J; Malmberg K-JK; Sandberg J; Gredmark-Russ S; Rooyackers O; Svensson MJ; Chambers BI; Eriksson L; Pernemalm MK; Bjorkstrom N; Aleman S; Ljunggren H-G; Klingstrom J; Stralin K; Norrby-Teglund A
Journal article: NEW ENGLAND JOURNAL OF MEDICINE. 2023;389(1):22-32
A Phase 3, Randomized Trial of Bulevirtide in Chronic Hepatitis D
Wedemeyer H; Aleman S; Brunetto MR; Blank A; Andreone P; Bogomolov P; Chulanov V; Mamonova N; Geyvandova N; Morozov V; Sagalova O; Stepanova T; Berger A; Manuilov D; Suri V; An Q; Da B; Flaherty J; Osinusi A; Liu Y; Merle U; Wiesch JSZ; Zeuzem S; Ciesek S; Cornberg M; Lampertico P
Article: BMC INFECTIOUS DISEASES. 2022;22(1):885
Monitoring the progress towards the elimination of hepatitis B and C in Sweden: estimation of core indicators for 2015 and 2018
Colombe S; Axelsson M; Aleman S; Duberg A-S; Ederth JL; Dahl V
Article: NATURE. 2022;611(7935):332-345
A multinational Delphi consensus to end the COVID-19 public health threat
Lazarus JV; Romero D; Kopka CJ; Karim SA; Abu-Raddad LJ; Almeida G; Baptista-Leite R; Barocas JA; Barreto ML; Bar-Yam Y; Bassat Q; Batista C; Bazilian M; Chiou S-T; del Rio C; Dore GJ; Gao GF; Gostin LO; Hellard M; Jimenez JL; Kang G; Lee N; Maticic M; McKee M; Nsanzimana S; Oliu-Barton M; Pradelski B; Pyzik O; Rabin K; Raina S; Rashid SF; Rathe M; Saenz R; Singh S; Trock-Hempler M; Villapol S; Yap P; Binagwaho A; Kamarulzaman A; El-Mohandes A
Article: EMBO MOLECULAR MEDICINE. 2022;14(10):e15821
A universal SARS-CoV DNA vaccine inducing highly cross-reactive neutralizing antibodies and T cells
Appelberg S; Ahlen G; Yan J; Nikouyan N; Weber S; Larsson O; Hoglund U; Aleman S; Weber F; Perlhamre E; Apro J; Gidlund E-K; Tuvesson O; Salati S; Cadossi M; Tegel H; Hober S; Frelin L; Mirazimi A; Sallberg M
Journal article: AMERICAN JOURNAL OF GASTROENTEROLOGY. 2022;117(10S):e858-e859
S1179 Bulevirtide Monotherapy at Low and High Dose in Patients With Chronic Hepatitis Delta: 24-Week Interim Data of the Phase 3 MYR301 Study
Lee S; Wedemeyer H; Aleman S; Brunetto M; Blank A; Andreone P; Bogomolov P; Chulanov V; Mamonova N; Geyvandova N; Morozov V; Sagalova O; Stepanova T; Manuilov D; Suri V; An Q; Flaherty JF; Osinusi A; Wiesch JSZ; Cornberg M; Zeuzem S; Lampertico P
Article: IMMUNITY. 2022;55(9):1732-1746.e5
Immunodeficiency syndromes differentially impact the functional profile of SARS-CoV-2-specific T cells elicited by mRNA vaccination
Gao Y; Cai C; Wullimann D; Niessl J; Rivera-Ballesteros O; Chen P; Lange J; Cuapio A; Blennow O; Hansson L; Mielke S; Nowak P; Vesterbacka J; Akber M; Perez-Potti A; Sekine T; Muller TR; Boulouis C; Kammann T; Parrot T; Muvva JR; Sobkowiak M; Healy K; Bogdanovic G; Muschiol S; Soderdahl G; Osterborg A; Hellgren F; Grifoni A; Weiskopf D; Sette A; Lore K; Chen MS; Ljungman P; Sandberg JK; Smith CIE; Bergman P; Ljunggren H-G; Aleman S; Buggert M
Article: HEPATOLOGY COMMUNICATIONS. 2022;6(9):2418-2430
Chronic hepatitis B virus infection and the risk of hepatocellular carcinoma by age and country of origin in people living in Sweden: A national register study
Duberg A-S; Lybeck C; Falt A; Montgomery S; Aleman S
Journal article: ZEITSCHRIFT FUR GASTROENTEROLOGIE. 2022;60(08):e471-e472
Bulevirtide monotherapy at low and high dose in patients with chronic hepatitis delta: 24-week interim data of the Phase 3 MYR301 study
Wedemeyer H; Aleman S; Brunetto M; Blank A; Andreone P; Bogomolov P; Chulanov V; Mamonova N; Geyvandova N; Morozov V; Sagalova O; Stepanova T; Manuilov D; Suri V; An Q; Flaherty J; Osinusi A; Schulze JZW; Cornberg M; Zeuzem S; Lampertico P
Article: JOURNAL OF CLINICAL IMMUNOLOGY. 2022;42(6):1130-1136
Neutralizing SARS-CoV-2 Antibodies in Commercial Immunoglobulin Products Give Patients with X-Linked Agammaglobulinemia Limited Passive Immunity to the Omicron Variant
Lindahl H; Klingstrom J; Da Silva Rodrigues R; Christ W; Chen P; Ljunggren H-G; Buggert M; Aleman S; Smith CIE; Bergman P
Journal article: JOURNAL OF HEPATOLOGY. 2022;77:s4-s5
GS006 Efficacy and safety of bulevirtide monotherapy given at 2 mg or 10 mg dose level once daily for treatment of chronic hepatitis delta: week 48 primary end point results from a phase 3 randomized, multicenter, parallel design study
Wedemeyer H; Aleman S; Brunetto M; Blank A; Andreone P; Bogomolov P; Chulanov V; Mamonova N; Geyvandova N; Viacheslav M; Sagalova O; Stepanova T; Manuilov D; Suri V; An Q; Flaherty JF; Osinusi A; Wiesch JSZ; Cornberg M; Zeuzem S; Lampertico P
Journal article: JOURNAL OF HEPATOLOGY. 2022;77:s829
SAT352 Integrated safety analysis of 24-week data from three phase 2 and one phase 3 clinical trials of bulevirtide monotherapy given at 2 mg and 10 mg dose level for treatment of chronic hepatitis delta
Lampertico P; Aleman S; Asselah T; Bourliere M; Streinu-Cercel A; Bogomolov P; Viacheslav M; Stepanova T; Lazar S; Suri V; Manuilov D; Ye L; Flaherty JF; Osinusi A; Brunetto M; Wedemeyer H
Journal article: JOURNAL OF HEPATOLOGY. 2022;77:s828
SAT351 Integrated efficacy analysis of 24-week data from two phase 2 and one phase 3 clinical trials of bulevirtide monotherapy given at 2 mg or 10 mg dose level for treatment of chronic hepatitis delta
Lampertico P; Aleman S; Blank A; Bogomolov P; Chulanov V; Mamonova N; Viacheslav M; Sagalova O; Stepanova T; Suri V; Manuilov D; Ye L; Flaherty JF; Osinusi A; Cornberg M; Brunetto M; Wedemeyer H
Journal article: JOURNAL OF HEPATOLOGY. 2022;77:s103
OS149 Treatment with bulevirtide improves patient-reported outcomes in patients with chronic hepatitis delta: An exploratory analysis of a Phase 3 trial at 48 weeks
Buti M; Wedemeyer H; Aleman S; Chulanov V; Viacheslav M; Sagalova O; Stepanova T; Gish RG; Lloyd A; Kaushik A; Suri V; Manuilov D; Osinusi A; Flaherty JF; Lampertico P
Journal article: JOURNAL OF HEPATOLOGY. 2022;77:s30
OS026 Liver stiffness predicts incident severe liver disease in patients with chronic liver disease
Hegmar H; Wester A; Aleman S; Backman J; Degerman E; Ekvall H; Lund K; Lundgren Å; Nasr P; Shahnavaz A; Vessby J; Westin J; Önnerhag K; Hagström H
Article: SCANDINAVIAN JOURNAL OF IMMUNOLOGY. 2022;96(1):e13195
The Karolinska KI/K COVID-19 immune atlas: An open resource for immunological research and educational purposes
Ljunggren H-G; Heggernes Ask E; Cornillet Jeannin M; Strunz B; Chen P; Rao Muvva J; Akber M; Buggert M; Chambers BJ; Cuapio Gomez A; Dzidic M; Filipovic I; Flodstrom-Tullberg M; Garcia M; Gorin J-B; Gredmark-Russ S; Hertwig L; Klingstrom J; Kokkinou E; Kvedaraite E; Lourda M; Mjosberg J; Maucourant C; Norrby-Teglund A; Palma Medina LM; Parrot T; Perez-Potti A; Ponzetta A; Ringqvist E; Rivera-Ballesteros O; Rooyackers O; Sandberg JK; Sandberg JT; Sekine T; Svensson M; Varnaite R; Wullimann D; Eriksson LI; Aleman S; Malmberg K-J; Stralin K; Bjorkstrom NK
Article: MOLECULAR MEDICINE. 2022;28(1):54
MAIT cell compartment characteristics are associated with the immune response magnitude to the BNT162b2 mRNA anti-SARS-CoV-2 vaccine
Boulouis C; Kammann T; Cuapio A; Parrot T; Gao Y; Mouchtaridi E; Wullimann D; Lange J; Chen P; Akber M; Ballesteros OR; Muvva JR; Smith CIE; Vesterbacka J; Kieri O; Nowak P; Bergman P; Buggert M; Ljunggren H-G; Aleman S; Sandberg JK
Article: JOURNAL OF CLINICAL IMMUNOLOGY. 2022;42(4):716-727
Elevated CD21^low B Cell Frequency Is a Marker of Poor Immunity to Pfizer-BioNTech BNT162b2 mRNA Vaccine Against SARS-CoV-2 in Patients with Common Variable Immunodeficiency
Bergman P; Wullimann D; Gao Y; Borgstrom EW; Norlin A-C; Enoksson SL; Aleman S; Ljunggren H-G; Buggert M; Smith CIE
Journal article: JHEP REPORTS. 2022;4(5):100462
Characteristics of hepatitis C virus resistance in an international cohort after a decade of direct-acting antivirals
Howe AYM; Rodrigo C; Cunningham EB; Douglas MW; Dietz J; Grebely J; Popping S; Sfalcin JA; Parczewski M; Sarrazin C; de Salazar A; Fuentes A; Sayan M; Quer J; Kjellin M; Kileng H; Mor O; Lennerstrand J; Fourati S; Di Maio VC; Chulanov V; Pawlotsky J-M; Harrigan PR; Ceccherini-Silberstein F; Garcia F
Article: THE LANCET GASTROENTEROLOGY AND HEPATOLOGY. 2022;7(5):396-415
Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study
Blach S; Terrault NA; Tacke F; Gamkrelidze I; Craxi A; Tanaka J; Waked I; Dore GJ; Abbas Z; Abdallah AR; Abdulla M; Aghemo A; Aho I; Akarca US; Alalwan AM; Blome MA; Al-Busafi SA; Aleman S; Alghamdi AS; Al-Hamoudi WK; Aljumah AA; Al-Naamani K; Al Serkal YM; Altraif IH; Anand AC; Anderson M; Andersson MI; Athanasakis K; Baatarkhuu O; Bakieva SR; Ben-Ari Z; Bessone F; Biondi MJ; Bizri ARN; Mello CEB; Brigida K; Brown KA; Brown RSJ; Bruggmann P; Brunetto MR; Busschots D; Buti M; Butsashvili M; Cabezas J; Chae C; Ivanova VC; Chan HLY; Cheinquer H; Cheng KJ; Cheon ME; Chien CH; Chien RN; Choudhuri G; Christensen PB; Chuang WL; Chulanov V; Cisneros LE; Coco B; Contreras FA; Cornberg M; Cramp ME; Crespo J; Cui F; Cunningham CW; Abou LD; Dalgard O; Dao DY; De Ledinghen V; Derbala MF; Deuba K; Dhindsa K; Djauzi S; Drazilova S; Duberg AS; Elbadri M; El-Sayed MH; Esmat G; Estes C; Ezzat S; Farkkila MA; Ferradini L; Ferraz MLG; Ferreira PRA; Kanizaj TF; Flisiak R; Frankova S; Fung J; Gamkrelidze A; Gane EJ; Garcia V; Garcia-Samaniego J; Gemilyan M; Genov J; Gheorghe LS; Gholam PM; Null AG; Gottfredsson M; Gray RT; Grebely J; Gschwantler M; Hajarizadeh B; Hamid SS; Hamoudi W; Hatzakis A; Hellard ME; Himatt S; Hofer H; Hrstic I; Hunyady B; Husa P; Husic-Selimovic A; Jafri WSM; Janicko M; Janjua NZ; Jarcuska P; Jaroszewicz J; Jerkeman A; Jeruma A; Jia J; Jonasson JG; Kaberg M; Kaita KDE; Null KSK; Kao JH; Kasymov OT; Hanku AK; Khamis F; Khamis J; Khan AG; Khandu L; Khoudri I; Kielland KB; Kim DY; Kodjoh N; Kondili LA; Krajden M; Krarup HB; Kristian P; Kwon JA; Lagging M; Laleman W; Lao WC; Lavanchy D; Lazaro P; Lazarus JV; Lee AU; Lee MH; Li MKK; Liakina V; Lim YS; Love A; Luksic B; Machekera SM; Malu AO; Marinho RT; Maticic M; Mekonnen HD; Mendes-Correa MC; Mendez-Sanchez N; Merat S; Meshesha BR; Midgard H; Mills M; Mohamed R; Mooneyhan E; Moreno C; Muljono DH; Mullhaupt B; Musabaev E; Muyldermans G; Nartey YA; Naveira MCM; Negro F; Nersesov AV; Njouom R; Ntagirabiri R; Nurmatov ZS; Obekpa SA; Oguche S; Olafsson S; Ong JP; Opare-Sem OK; Orrego M; Ovrehus AL; Pan CQ; Papatheodoridis GV; Peck-Radosavljevic M; Pessoa MG; Phillips RO; Pimenov N; Plaseska-Karanfilska D; Prabdial-Sing NN; Puri P; Null HQ; Rahman A; Ramji A; Razavi-Shearer DM; Razavi-Shearer K; Ridruejo E; Rios-Hincapie CY; Rizvi SMS; Robaeys GKMM; Roberts LR; Roberts SK; Ryder SD; Sadirova S; Saeed U; Safadi R; Sagalova O; Said SS; Salupere R; Sanai FM; Sanchez-Avila JF; Saraswat VA; Sarrazin C; Sarybayeva G; Seguin-Devaux C; Sharara AI; Sheikh M; Shewaye AB; Sievert W; Simojoki K; Simonova MY; Sonderup MW; Spearman CW; Sperl J; Stauber RE; Stedman CAM; Su TH; Suleiman A; Sypsa V; Antabak NT; Tan SS; Tergast TL; Thurairajah PH; Tolmane I; Tomasiewicz K; Tsereteli M; Uzochukwu BSC; Van de Vijver DAMC; van Santen DK; Van Vlierberghe H; Van Welzen B; Vanwolleghem T; Velez-Moller P; Villamil FG; Vince A; Waheed Y; Weis N; Wong VWS; Yaghi CG; Yesmembetov K; Yosry A; Yuen MF; Yunihastuti E; Zeuzem S; Zuckerman E; Razavi HA
Journal article: DIGESTIVE AND LIVER DISEASE. 2022;54:s24-s25
Bulevirtide monotherapy at low and high dose in patients with chronic hepatitis delta: 24 weeks interim data of the phase 3 MYR301 study
Wedemeyer H; Aleman S; Andreone P; Blank A; Brunetto M; Bogomolov P; Chulanov V; Geyvandova N; Hilgard G; Mamonova N; Merle U; Viacheslav M; Sagalova O; Stepanova T; Wiesch JSZ; Zotov S; Zeuzem S; Lampertico P
Article: NATURE MEDICINE. 2022;28(3):472-476
Ancestral SARS-CoV-2-specific T cells cross-recognize the Omicron variant
Gao Y; Cai C; Grifoni A; Muller TR; Niessl J; Olofsson A; Humbert M; Hansson L; Osterborg A; Bergman P; Chen P; Olsson A; Sandberg JK; Weiskopf D; Price DA; Ljunggren H-G; Karlsson AC; Sette A; Aleman S; Buggert M
Article: EUROPEAN JOURNAL OF IMMUNOLOGY. 2022;52(3):503-510
COVID-19-specific metabolic imprint yields insights into multiorgan system perturbations
Cornillet M; Strunz B; Rooyackers O; Ponzetta A; Chen P; Muvva JR; Akber M; Buggert M; Chambers BJ; Dzidic M; Filipovic I; Gorin J-B; Gredmark-Russ S; Hertwig L; Klingstrom J; Kokkinou E; Kvedaraite E; Lourda M; Mjosberg J; Maucourant C; Norrby-Teglund A; Parrot T; Perez-Potti A; Rivera-Ballesteros O; Sandberg JK; Sandberg JT; Sekine T; Svensson M; Varnaite R; Eriksson LI; Aleman S; Stralin K; Ljunggren H-G; Bjorkstrom NK
Article: MED. 2022;3(2):137-153.e3
Salivary IgG to SARS-CoV-2 indicates seroconversion and correlates to serum neutralization in mRNA-vaccinated immunocompromised individuals
Healy K; Pin E; Chen P; Soderdahl G; Nowak P; Mielke S; Hansson L; Bergman P; Smith CIE; Ljungman P; Valentini D; Blennow O; Osterborg A; Gabarrini G; Al-Manei K; Alkharaan H; Sobkowiak MJ; Yousef J; Mravinacova S; Cuapio A; Xu X; Akber M; Lore K; Hellstrom C; Muschiol S; Bogdanovic G; Buggert M; Ljunggren H-G; Hober S; Nilsson P; Aleman S; Chen MS
Article: MOLECULAR MEDICINE. 2022;28(1):20
NK cell frequencies, function and correlates to vaccine outcome in BNT162b2 mRNA anti-SARS-CoV-2 vaccinated healthy and immunocompromised individuals
Cuapio A; Boulouis C; Filipovic I; Wullimann D; Kammann T; Parrot T; Chen P; Akber M; Gao Y; Hammer Q; Strunz B; Potti AP; Ballesteros OR; Lange J; Muvva JR; Bergman P; Blennow O; Hansson L; Mielke S; Nowak P; Soderdahl G; Osterborg A; Smith CIE; Bogdanovic G; Muschiol S; Hellgren F; Lore K; Sobkowiak MJ; Gabarrini G; Healy K; Chen MS; Alici E; Bjorkstrom NK; Buggert M; Ljungman P; Sandberg JK; Aleman S; Ljunggren H-G
Journal article: NATURE MEDICINE. 2022
Ancestral SARS-CoV-2-specific T cells cross-recognize Omicron
Gao Y; Cai C; Grifoni A; Müller TR; Niessl J; Olofsson A; Humbert M; Hansson L; Österborg A; Bergman P; Chen P; Olsson A; Sandberg JK; Weiskopf D; Price DA; Ljunggren H-G; Karlsson AC; Sette A; Aleman S; Buggert M
Article: CLINICAL & TRANSLATIONAL IMMUNOLOGY. 2022;11(3):e1379
Probabilistic classification of anti-SARS-CoV-2 antibody responses improves seroprevalence estimates
Dopico XC; Muschiol S; Grinberg NF; Aleman S; Sheward DJ; Hanke L; Ahl M; Vikstrom L; Forsell M; Coquet JM; McInerney G; Dillner J; Bogdanovic G; Murrell B; Albert J; Wallace C; Hedestam GBK
Article: FRONTIERS IN IMMUNOLOGY. 2022;13:1079995
Persistence of salivary antibody responses after COVID-19 vaccination is associated with oral microbiome variation in both healthy and people living with HIV
Ghorbani M; Al-Manei K; Naud S; Healy K; Gabarrini G; Sobkowiak MJ; Chen P; Ray S; Akber M; Muschiol S; Bogdanovic G; Bergman P; Ljungman P; Buggert M; Ljunggren H-G; Pin E; Nowak P; Aleman S; Saellberg Chen M
Article: LAKARTIDNINGEN. 2021;118:21163
[Insights from creating a covid-19 biobank in Sweden].
Ljunggren H-G; Strålin K; Chen P; Cornillet M; Rooijackers O; I Eriksson L; Aleman S; Björkström N
Article: EBIOMEDICINE. 2021;74:103705
Safety and efficacy of the mRNA BNT162b2 vaccine against SARS-CoV-2 in five groups of immunocompromised patients and healthy controls in a prospective open-label clinical trial
Bergman P; Blennow O; Hansson L; Mielke S; Nowak P; Chen P; Soderdahl G; Osterborg A; Smith CIE; Wullimann D; Vesterbacka J; Lindgren G; Blixt L; Friman G; Wahren-Borgstrom E; Nordlander A; Gomez AC; Akber M; Valentini D; Norlin A-C; Thalme A; Bogdanovic G; Muschiol S; Nilsson P; Hober S; Lore K; Chen MS; Buggert M; Ljunggren H-G; Ljungman P; Aleman S
Article: PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA. 2021;118(40):e2109123118
High-dimensional profiling reveals phenotypic heterogeneity and disease-specific alterations of in COVID-19
Lourda M; Dzidic M; Hertwig L; Bergsten H; Medina LMP; Sinha I; Kvedaraite E; Chen P; Muvva JR; Gorin J-B; Cornillet M; Emgard J; Moll K; Garcia M; Maleki KT; Klingstrom J; Michaelsson J; Flodstrom-Tullberg M; Brighenti S; Buggert M; Mjosberg J; Malmberg K-J; Sandberg JK; Henter J-I; Folkesson E; Gredmark-Russ S; Sonnerborg A; Eriksson LI; Rooyackers O; Aleman S; Stralin K; Ljunggren H-G; Bjorkstrom NK; Svensson M; Ponzetta A; Norrby-Teglund A; Chambers BJ
Article: LIVER INTERNATIONAL. 2021;41(9):2024-2031
Hepatitis C elimination in Sweden: Progress, challenges and opportunities for growth in the time of COVID-19
Blach S; Blome M; Duberg A-S; Jerkeman A; Kaberg M; Klasa P-E; Lagging M; Razavi-Shearer D; Razavi H; Aleman S
Article: JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (JAMA). 2021;326(6):499-518
Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19 AMeta-analysis
Shankar-Hari M; Vale CL; Godolphin PJ; Fisher D; Higgins JPT; Spiga F; Savovic J; Tierney J; Baron G; Benbenishty JS; Berry LR; Broman N; Cavalcanti AB; Colman R; De Buyser SL; Derde LPG; Domingo P; Omar SF; Fernandez-Cruz A; Feuth T; Garcia F; Garcia-Vicuna R; Gonzalez-Alvaro I; Gordon AC; Haynes R; Hermine O; Horby PW; Horick NK; Kumar K; Lambrecht BN; Landray MJ; Leal L; Lederer DJ; Lorenzi E; Mariette X; Merchante N; Misnan NA; Mohan SV; Nivens MC; Oksi J; Perez-Molina JA; Pizov R; Porcher R; Postma S; Rajasuriar R; Ramanan AV; Ravaud P; Reid PD; Rutgers A; Sancho-Lopez A; Seto TB; Sivapalasingam S; Soin AS; Staplin N; Stone JH; Strohbehn GW; Sunden-Cullberg J; Torre-Cisneros J; Tsai LW; van Hoogstraten H; van Meerten T; Veiga VC; Westerweel PE; Murthy S; Diaz JV; Marshall JC; Sterne JAC
Article: JOURNAL OF INFECTIOUS DISEASES. 2021;224(3):407-414
Persisting Salivary IgG Against SARS-CoV-2 at 9 Months After Mild COVID-19: A Complementary Approach to Population Surveys
Alkharaan H; Bayati S; Hellstrom C; Aleman S; Olsson A; Lindahl K; Bogdanovic G; Healy K; Tsilingaridis G; De Palma P; Hober S; Manberg A; Nilsson P; Pin E; Chen MS
Article: JHEP REPORTS. 2021;3(4):100318
Human MAIT cells endowed with HBV specificity are cytotoxic and migrate towards HBV-HCC while retaining antimicrobial functions
Healy K; Pavesi A; Parrot T; Sobkowiak MJ; Reinsbach SE; Davanian H; Tan AT; Aleman S; Sandberg JK; Bertoletti A; Chen MS
Journal article: GASTROHEP. 2021;3(4):272
Reply
Lybeck C; Duberg A; Aleman S; Montgomery S; Bruce D
Journal article: JOURNAL OF PEDIATRIC SURGERY. 2021;56(6):1247-1251
Giant omphalocele: Delayed closure using the San Martin technique following epithelialization of the membrane
Boglione M; Aleman S; Reusmann A; Rubio M; Marcelo B
Journal article: GASTROHEP. 2021;3(3):185-195
Risk of extrahepatic cancer in a nationwide cohort of hepatitis C virus infected persons treated with direct‐acting antivirals
Lybeck C; Bruce D; Montgomery SM; Aleman S; Duberg A
Article: JCI INSIGHT. 2021;6(5):140074
Expansion of donor-unrestricted MAIT cells with enhanced cytolytic function suitable for TCR redirection
Parrot T; Healy K; Boulouis C; Sobkowiak MJ; Leeansyah E; Aleman S; Bertoletti A; Chen MS; Sandberg JK
Article: CLINICS AND RESEARCH IN HEPATOLOGY AND GASTROENTEROLOGY. 2021;45(2):101564
Hepatitis C standards of care: A review of good practices since the advent of direct-acting antiviral therapy
Lazarus JV; Picchio CA; Guy D; Aleman S; James C; Nava FA; Ovrehus A; Turnes J; Ward JW; Ustianowski A
Article: PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA. 2021;118(6):e2018587118
Major alterations in the mononuclear phagocyte landscape associated with COVID-19 severity
Kvedaraite E; Hertwig L; Sinha I; Ponzetta A; Myrberg IH; Lourda M; Dzidic M; Akber M; Klingstrom J; Folkesson E; Muvva JR; Chen P; Gredmark-Russ S; Brighenti S; Norrby-Teglund A; Eriksson LI; Rooyackers O; Aleman S; Stralin K; Ljunggren H-G; Ginhoux F; Bjorkstrom NK; Henter J-I; Svensson M
Article: PLOS ONE. 2021;16(6):e0253710
Mortality among amphetamine users with hepatitis C virus infection: A nationwide study
Gahrton C; Hakansson A; Kaberg M; Jerkeman A; Habel H; Dalgard O; Duberg A-S; Aleman S
Article: CLINICAL & TRANSLATIONAL IMMUNOLOGY. 2021;10(7):e1306
SARS-CoV-2-specific humoral and cellular immunity persists through 9 months irrespective of COVID-19 severity at hospitalisation
Sandberg JT; Varnaite R; Christ W; Chen P; Muvva JR; Maleki KT; Garcia M; Dzidic M; Folkesson E; Skagerberg M; Ahlen G; Frelin L; Sallberg M; Eriksson LI; Rooyackers O; Sonnerborg A; Buggert M; Bjorkstrom NK; Aleman S; Stralin K; Klingstrom J; Ljunggren H-G; Blom K; Gredmark-Russ S
Article: GUT. 2020;69(12):2203-2213
Evidence for B cell maturation but not trained immunity in uninfected infants exposed to hepatitis C virus
Lutckii A; Strunz B; Zhirkov A; Filipovich O; Rukoiatkina E; Gusev D; Lobzin Y; Fischler B; Aleman S; Sallberg M; Bjorkstrom NK
Article: HEPATOLOGY. 2020;72(4):1177-1190
Long-Term Study of Hepatitis Delta Virus Infection at Secondary Care Centers: The Impact of Viremia on Liver-Related Outcomes
Kamal H; Westman G; Falconer K; Duberg A-S; Weiland O; Haverinen S; Wejstal R; Carlsson T; Kampmann C; Larsson SB; Bjorkman P; Nystedt A; Cardell K; Svensson S; Stenmark S; Wedemeyer H; Aleman S
Article: CELL. 2020;183(1):158-168.e14
Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19
Sekine T; Perez-Potti A; Rivera-Ballesteros O; Stralin K; Gorin J-B; Olsson A; Llewellyn-Lacey S; Kamal H; Bogdanovic G; Muschiol S; Wullimann DJ; Kammann T; Emgard J; Parrot T; Folkesson E; Rooyackers O; Eriksson LI; Henter J-I; Sonnerborg A; Allander T; Albert J; Nielsen M; Klingstrom J; Gredmark-Russ S; Bjorkstrom NK; Sandberg JK; Price DA; Ljunggren H-G; Aleman S; Buggert M
Article: SCIENCE IMMUNOLOGY. 2020;5(51):eabe1670
MAIT cell activation and dynamics associated with COVID-19 disease severity
Parrot T; Gorin J-B; Ponzetta A; Maleki KT; Kammann T; Emgard J; Perez-Potti A; Sekine T; Rivera-Ballesteros O; Gredmark-Russ S; Rooyackers O; Folkesson E; Eriksson LI; Norrby-Teglund A; Ljunggren H-G; Bjorkstrom NK; Aleman S; Buggert M; Klingstrom J; Stralin K; Sandberg JK
Article: SCIENCE IMMUNOLOGY. 2020;5(50):eabd6832
Natural killer cell immunotypes related to COVID-19 disease severity
Maucourant C; Filipovic I; Ponzetta A; Aleman S; Cornillet M; Hertwig L; Strunz B; Lentini A; Reinius B; Brownlie D; Cuapio A; Ask EH; Hull RM; Haroun-Izquierdo A; Schaffer M; Klingstrom J; Folkesson E; Buggert M; Sandberg JK; Eriksson LI; Rooyackers O; Ljunggren H-G; Malmberg K-J; Michaelsson J; Marquardt N; Hammer Q; Stralin K; Bjorkstrom NK
Journal article: JOURNAL OF HEPATOLOGY. 2020;73:s379
THU480 Risk of hepatocellular carcinoma in hepatitis D co-infected patients compared to hepatitis B mono-infected patients: a systematic review and meta-analysis
Kamal H; Romina F; Johanna S; Brusselaers N; Aleman S
Article: LIVER INTERNATIONAL. 2020;40(8):1832-1840
Frequent loss to follow-up after diagnosis of hepatitis C virus infection: A barrier towards the elimination of hepatitis C virus
Aleman S; Soderholm J; Busch K; Kovamees J; Duberg A-S
Article: SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY. 2020;55(5):574-580
High risk of non-alcoholic liver disease mortality in patients with chronic hepatitis C with illicit substance use disorder
Kaberg M; Larsson SB; Jerkeman A; Nystedt A; Duberg A-S; Kovamees J; Ydreborg M; Aleman S; Busch K; Blome MA; Weiland O; Soderholm J
Article: LAKARTIDNINGEN. 2020;117:F3HW
Covid-19 – uppdatering om klinisk bild och behandling.
Glans H; Sönnerborg A; Aleman S
Article: NEW ENGLAND JOURNAL OF MEDICINE. 2020;382(11):1018-1028
Association of Aspirin with Hepatocellular Carcinoma and Liver-Related Mortality
Simon TG; Duberg A-S; Aleman S; Chung RT; Chan AT; Ludvigsson JF
Article: SCIENTIFIC REPORTS. 2020;10(1):2081
Plasma FABP4 is associated with liver disease recovery during treatment-induced clearance of chronic HCV infection
Gorin J-B; Malone DFG; Strunz B; Carlsson T; Aleman S; Bjorkstrom NK; Falconer K; Sandberg JK
Article: SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY. 2020;55(2):178-183
Sustained clinical benefit, improved quality of life, and reduced intestinal surgery from maintenance infliximab treatment in inflammatory bowel disease*
Hossain A; Lordal M; Olsson AE; Storlahls A; Aleman S; Eberhardson M; Befrits R
Article: CANCER EPIDEMIOLOGY, BIOMARKERS AND PREVENTION. 2020;29(1):63-70
Hepatitis C Virus Infection and the Temporal Trends in the Risk of Liver Cancer: A National Register-Based Cohort Study in Sweden
Batyrbekova N; Aleman S; Lybeck C; Montgomery S; Duberg A-S
Article: CLINICAL & TRANSLATIONAL IMMUNOLOGY. 2020;9(12):e1224
Innate lymphoid cell composition associates with COVID-19 disease severity
Garcia M; Kokkinou E; Carrasco Garcia A; Parrot T; Palma Medina LM; Maleki KT; Christ W; Varnaite R; Filipovic I; Ljunggren H-G; Bjorkstrom NK; Folkesson E; Rooyackers O; Eriksson LI; Sonnerborg A; Aleman S; Stralin K; Gredmark-Russ S; Klingstrom J; Mjosberg J
Article: CLINICAL INFECTIOUS DISEASES. 2019;69(12):2218-2227
The Consensus Hepatitis C Cascade of Care: Standardized Reporting to Monitor Progress Toward Elimination
Safreed-Harmon K; Blach S; Aleman S; Bollerup S; Cooke G; Dalgard O; Dillon JF; Dore GJ; Duberg A-S; Grebely J; Kielland KB; Midgard H; Porter K; Razavi H; Tyndall M; Weis N; Lazarus JV
Article: BMC INFECTIOUS DISEASES. 2019;19(1):955
Prevalence of Viremic hepatitis C, hepatitis B, and HIV infection, and vaccination status among prisoners in Stockholm County
Gahrton C; Westman G; Lindahl K; Oehrn F; Dalgard O; Lidman C; Nilsson L-H; Said K; Duberg A-S; Aleman S
Article: ANNALS OF INTERNAL MEDICINE. 2019;171(5):318-327
Lipophilic Statins and Risk for Hepatocellular Carcinoma and Death in Patients With Chronic Viral Hepatitis: Results From a Nationwide Swedish Population
Simon TG; Duberg A-S; Aleman S; Hagstrom H; Nguyen LH; Khalili H; Chung RT; Ludvigsson JF
Article: SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY. 2019;54(8):1042-1050
Effect of the baseline Y93H resistance-associated substitution in HCV genotype 3 for direct-acting antiviral treatment: real-life experience from a multicenter study in Sweden and Norway
Kjellin M; Kileng H; Akaberi D; Palanisamy N; Duberg A-S; Danielsson A; Kristiansen MG; Nojd J; Aleman S; Gutteberg T; Goll R; Lannergard A; Lennerstrand J
Journal article: GASTROENTEROLOGY. 2019;156(6):s-1200
496 – Aspirin Use is Associated with Reduced Risk for Incident Hepatocellular Carcinoma in Patients with Chronic Viral Hepatitis: Results from a Nationwide Population
Simon TG; Duberg A-S; Aleman S; Chung RT; Ludvigsson JF
Article: EUROPEAN JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY. 2019;31(4):506-513
Long-term follow-up after cure from chronic hepatitis C virus infection shows occult hepatitis and a risk of hepatocellular carcinoma in noncirrhotic patients
Lybeck C; Brenndorfer ED; Sallberg M; Montgomery SM; Aleman S; Duberg A-S
Article: EUROPEAN JOURNAL OF IMMUNOLOGY. 2019;49(1):133-143
Tissue-resident MAIT cell populations in human oral mucosa exhibit an activated profile and produce IL-17
Sobkowiak MJ; Davanian H; Heymann R; Gibbs A; Emgard J; Dias J; Aleman S; Kruger-Weiner C; Moll M; Tjernlund A; Leeansyah E; Chen MS; Sandberg JK
Article: EUROPEAN JOURNAL OF IMMUNOLOGY. 2018;48(8):1329-1335
IL13R2 expression identifies tissue-resident IL-22-producing PLZF⁺ innate Tcells in the human liver
Paquin-Proulx D; Greenspun BC; Pasquet L; Strunz B; Aleman S; Falconer K; Terabe M; Berzofsky JA; Sandberg JK; Melum E; Nixon DF; Bjorkstrom NK
Article: JOURNAL OF VIRAL HEPATITIS. 2018;25(7):802-810
Cirrhosis, high age and high body mass index are risk factors for persisting advanced fibrosis after sustained virological response in chronic hepatitis C
Hedenstierna M; Nangarhari A; El-Sabini A; Weiland O; Aleman S
Article: THE LANCET GASTROENTEROLOGY AND HEPATOLOGY. 2018;3(6):383-403
Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study
Razavi-Shearer D; Gamkrelidze I; Nguyen MH; Chen D-S; Van Damme P; Abbas Z; Abdulla M; Abou Rached A; Adda D; Aho I; Akarca U; Al Ali FH; Al Lawati F; Al Naamani K; Alashgar HI; Alavian SM; Alawadhi S; Albillos A; Al-Busafi SA; Aleman S; Alfaleh FZ; Aljumah AA; Anand AC; Nguyen TA; Arends JE; Arkkila P; Athanasakis K; Bane A; Ben-Ari Z; Berg T; Bizri AR; Blach S; Brandao Mello CE; Brandon SM; Bright B; Bruggmann P; Brunetto M; Buti M; Chan HLY; Chaudhry A; Chien R-N; Choi MS; Christensen PB; Chuang W-L; Chulanov V; Clausen MR; Colombo M; Cornberg M; Cowie B; Craxi A; Croes EA; Alberto Cuellar D; Cunningham C; Desalegn H; Drazilova S; Duberg A-S; Egeonu SS; El-Sayed MH; Estes C; Falconer K; Ferraz MLG; Ferreira PR; Flisiak R; Frankova S; Gaeta GB; Garcia-Samaniego J; Genov J; Gerstoft J; Goldis A; Gountas I; Gray R; Pessoa MG; Hajarizadeh B; Hatzakis A; Hezode C; Himatt SM; Hoepelman A; Hrstic I; Hui Y-TT; Husa P; Jahis R; Janjua NZ; Jarcuska P; Jaroszewicz J; Kaymakoglu S; Kershenobich D; Kondili LA; Konysbekova A; Krajden M; Kristian P; Laleman W; Lao W-CC; Layden J; Lazarus JV; Lee M-H; Liakina V; Lim Y-SS; Loo C-KK; Luksic B; Malekzadeh R; Malu AO; Mamatkulov A; Manns M; Marinho RT; Maticic M; Mauss S; Memon MS; Mendes Correa MC; Mendez-Sanchez N; Merat S; Metwally AM; Mohamed R; Mokhbat JE; Moreno C; Mossong J; Mourad FH; Mullhaupt B; Murphy K; Musabaev E; Nawaz A; Nde HM; Negro F; Nersesov A; Van TTN; Njouom R; Ntagirabiri R; Nurmatov Z; Obekpa S; Ocama P; Oguche S; Omede O; Omuemu C; Opare-Sem O; Opio CK; Ormeci N; Papatheodoridis G; Pasini K; Pimenov N; Poustchi H; Quang TD; Qureshi H; Ramji A; Razavi-Shearer K; Redae B; Reesink HW; Yaneth Rios C; Rjaskova G; Robbins S; Roberts LR; Roberts SK; Ryder SD; Safadi R; Sagalova O; Salupere R; Sanai FM; Sanchez-Avila JF; Saraswat V; Sarrazin C; Schmelzer JD; Schreter I; Scott J; Seguin-Devaux C; Shah SR; Sharara AI; Sharma M; Shiha GE; Shin T; Sievert W; Sperl J; Starkel P; Stedman C; Sypsa V; Tacke F; Tan SS; Tanaka J; Tomasiewicz K; Urbanek P; van der Meer AJ; Van Vlierberghe H; Vella S; Vince A; Waheed Y; Waked I; Walsh N; Weis N; Wong VW; Woodring J; Yaghi C; Yang H-I; Yang C-L; Yesmembetov K; Yosry A; Yuen M-F; Yusuf MAM; Zeuzem S; Razavi H
Article: PLOS ONE. 2018;13(1):e0190146
Policy responses to hepatitis C in the Nordic countries: Gaps and discrepant reporting in the Hep-Nordic study
Safreed-Harmon K; Hetherington KL; Aleman S; Alho H; Dalgard O; Frisch T; Gottfredsson M; Weis N; Lazarus JV
Journal article: JOURNAL OF IMMUNOLOGY. 2017;198(1_Supplement):149.8
MAIT cells in the human oral mucosa are activated and perforinlow
Sobkowiak M; Davanian H; Tjernlund A; Gibbs A; Nayak S; Leeansyah E; Dias J; Heymann R; Krüger-Weiner C; Aleman S; Moll M; Sällberg-Chen M; Sandberg JK
Article: JOURNAL OF VIROLOGY. 2017;91(9):e00010-e00017
Hepatitis C Virus-Specific T Cell Receptor mRNA-Engineered Human T Cells: Impact of Antigen Specificity on Functional Properties
Balasiddaiah A; Davanian H; Aleman S; Pasetto A; Frelin L; Sallberg M; Lohmann V; Koh S; Bertoletti A; Chen M
Article: THE LANCET GASTROENTEROLOGY AND HEPATOLOGY. 2017;2(5):325-336
Hepatitis C virus prevalence and level of intervention required to achieve the WHO targets for elimination in the European Union by 2030: a modelling study
Razavi H; Robbins S; Zeuzem S; Negro F; Buti M; Duberg A-S; Roudot-Thoraval F; Craxi A; Manns M; Marinho RT; Hunyady B; Colombo M; Aleman S; Antonov K; Arkkila P; Athanasakis K; Blach S; Blachier M; Blasco AJ; Calinas F; Calleja JL; Christensen PB; Cramp ME; Croes E; de Knegt RJ; de Ledinghen V; Delile J-M; Estes C; Falconer K; Farkkila M; Flisiak R; Frankova S; Gamkrelidze I; Garcia-Samaniego J; Genov J; Gerstoft J; Gheorghe L; Goldis A; Gountas I; Gregorcic S; Gschwantler M; Gunter J; Halota W; Harcouet L; Hezode C; Hoffmann P; Horvath G; Hrstic I; Jarcuska P; Jelev D; Jeruma A; Kaberg M; Kieran J; Kondili LA; Kotzev I; Krarup H; Kristian P; Lagging M; Laleman W; Lazaro P; Liakina V; Luksic B; Maimets M; Makara M; Mateva L; Maticic M; Mennini FS; Mitova R; Moreno C; Mossong J; Murphy K; Nde H; Nemecek V; Nonkovic D; Norris S; Oltman M; Ovrehus ALH; Papatheodoridis G; Pasini K; Razavi-Shearer D; Razavi-Shearer K; Reesink HW; Reic T; Rozentale B; Ryder SD; Salupere R; Sarmento-Castro R; Sarrazin C; Schmelzer JD; Schreter I; Seguin-Devaux C; Simojoki K; Simonova M; Smit PJ; Souliotis K; Speiciene D; Sperl J; Starkel P; Struck D; Sypsa V; Thornton L; Tolmane I; Tomasiewicz K; Valantinas J; Van Damme P; de Vijver DV; van der Meer AJ; van Santen D; Van Vlierberghe H; Vandijck D; Vella S; Videcnik-Zorman J; Vogel W; Weis N; Hatzakis A
Article: JOURNAL OF HEPATOLOGY. 2017;66(3):485-493
Risk of cirrhosis-related complications in patients with advanced fibrosis following hepatitis C virus eradication
van der Meer AJ; Feld JJ; Hofer H; Almasio PL; Calvaruso V; Fernandez-Rodriguez CM; Aleman S; Ganne-Carrie N; D'Ambrosio R; Pol S; Trapero-Marugan M; Maan R; Moreno-Otero R; Mallet V; Hultcrantz R; Weiland O; Rutter K; Di Marco V; Alonso S; Bruno S; Colombo M; de Knegt RJ; Veldt BJ; Hansen BE; Janssen HLA
Article: THE LANCET GASTROENTEROLOGY AND HEPATOLOGY. 2017;2(3):161-176
Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study
Blach S; Zeuzem S; Manns M; Altraif I; Duberg A-S; Muljono DH; Waked I; Alavian SM; Lee M-H; Negro F; Abaalkhail F; Abdou A; Abdulla M; Abou Rached A; Aho I; Akarca U; Al Ghazzawi I; Al Kaabi S; Al Lawati F; Al Namaani K; Al Serkal Y; Al-Busafi SA; Al-Dabal L; Aleman S; Alghamdi AS; Aljumah AA; Al-Romaihi HE; Andersson MI; Arendt V; Arkkila P; Assiri AM; Baatarkhuu O; Bane A; Ben-Ari Z; Bergin C; Bessone F; Bihl F; Bizri AR; Blachier M; Blasco AJ; Mello CEB; Bruggmann P; Brunton CR; Calinas F; Chan HLY; Chaudhry A; Cheinquer H; Chen C-J; Chien R-N; Choi MS; Christensen PB; Chuang W-L; Chulanov V; Cisneros L; Clausen MR; Cramp ME; Craxi A; Croes EA; Dalgard O; Daruich JR; de Ledinghen V; Dore GJ; El-Sayed MH; Ergor G; Esmat G; Estes C; Falconer K; Farag E; Ferraz MLG; Ferreira PR; Flisiak R; Frankova S; Gamkrelidze I; Gane E; Garcia-Samaniego J; Khan AG; Gountas I; Goldis A; Gottfredsson M; Grebely J; Gschwantler M; Pessoa MG; Gunter J; Hajarizadeh B; Hajelssedig O; Hamid S; Hamoudi W; Hatzakis A; Himatt SM; Hofer H; Hrstic I; Hui Y-T; Hunyady B; Idilman R; Jafri W; Jahis R; Janjua NZ; Jarcuska P; Jeruma A; Jonasson JG; Kamel Y; Kao J-H; Kaymakoglu S; Kershenobich D; Khamis J; Kim YS; Kondili L; Koutoubi Z; Krajden M; Krarup H; Lai M-S; Laleman W; Lao W-C; Lavanchy D; Lazaro P; Leleu H; Lesi O; Lesmana LA; Li M; Liakina V; Lim Y-S; Luksic B; Mahomed A; Maimets M; Makara M; Malu AO; Marinho RT; Marotta P; Mauss S; Memon MS; Correa MCM; Mendez-Sanchez N; Merat S; Metwally AM; Mohamed R; Moreno C; Mourad FH; Mullhaupt B; Murphy K; Nde H; Njouom R; Nonkovic D; Norris S; Obekpa S; Oguche S; Olafsson S; Oltman M; Omede O; Omuemu C; Opare-Sem O; Ovrehus ALH; Owusu-Ofori S; Oyunsuren TS; Papatheodoridis G; Pasini K; Peltekian KM; Phillips RO; Pimenov N; Poustchi H; Prabdial-Sing N; Qureshi H; Ramji A; Razavi-Shearer D; Razavi-Shearer K; Redae B; Reesink HW; Ridruejo E; Robbins S; Roberts LR; Roberts SK; Rosenberg WM; Roudot-Thoraval F; Ryder SD; Safadi R; Sagalova O; Salupere R; Sanai FM; Avila JFS; Saraswat V; Sarmento-Castro R; Sarrazin C; Schmelzer JD; Schreter I; Seguin-Devaux C; Shah SR; Sharara AI; Sharma M; Shevaldin A; Shiha GE; Sievert W; Sonderup M; Souliotis K; Speiciene D; Sperl J; Starkel P; Stauber RE; Stedman C; Struck D; Su T-H; Sypsa V; Tan S-S; Tanaka J; Thompson AJ; Tolmane I; Tomasiewicz K; Valantinas J; Van Damme P; van der Meer AJ; van Thiel I; Van Vlierberghe H; Vince A; Vogel W; Wedemeyer H; Weis N; Wong VWS; Yaghi C; Yosry A; Yuen M-F; Yunihastuti E; Yusuf A; Zuckerman E; Razavi H
Article: SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY. 2017;52(1):61-68
Prevalence and comorbidities of chronic hepatitis C: a nationwide population-based register study in Sweden
Busch K; Waldenstrom J; Lagging M; Aleman S; Weiland O; Kovamees J; Duberg A-S; Soderholm J
Article: HAEMOPHILIA. 2016;22(6):e494-e501
Long-term liver-related morbidity and mortality related to chronic hepatitis C virus infection in Swedish patients with inherited bleeding disorders
Holmstrom M; Nangarhari A; Ohman J; Duberg A-S; Majeed A; Aleman S
Article: CLINICAL INFECTIOUS DISEASES. 2016;63(6):723-729
Diabetes and Cirrhosis Are Risk Factors for Hepatocellular Carcinoma After Successful Treatment of Chronic Hepatitis C
Hedenstierna M; Nangarhari A; Weiland O; Aleman S
Article: ALIMENTARY PHARMACOLOGY AND THERAPEUTICS. 2015;41(6):532-543
Long-term follow-up of successful hepatitis C virus therapy: waning immune responses and disappearance of liver disease are consistent with cure
Hedenstierna M; Weiland O; Brass A; Bankwitz D; Behrendt P; Uhnoo I; Aleman S; Cardell K; Fryden A; Norkrans G; Eilard A; Glaumann H; Pietschmann T; Sallberg M; Brenndorfer ED
Article: SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY. 2015;50(2):233-244
The future disease burden of hepatitis C virus infection in Sweden and the impact of different treatment strategies
Duberg A-S; Blach S; Falconer K; Kaberg M; Razavi H; Aleman S
Article: JOURNAL OF VIRAL HEPATITIS. 2014;21:60-89
Strategies to manage hepatitis C virus (HCV) disease burden
Wedemeyer H; Duberg AS; Buti M; Rosenberg WM; Frankova S; Esmat G; Ormeci N; Van Vlierberghe H; Gschwantler M; Akarca U; Aleman S; Balik I; Berg T; Bihl F; Bilodeau M; Blasco AJ; Brandao Mello CE; Bruggmann P; Calinas F; Calleja JL; Cheinquer H; Christensen PB; Clausen M; Coelho HSM; Cornberg M; Cramp ME; Dore GJ; Doss W; El-Sayed MH; Ergor G; Estes C; Falconer K; Felix J; Ferraz MLG; Ferreira PR; Garcia-Samaniego J; Gerstoft J; Giria JA; Goncales FLJ; Guimaraes Pessoa M; Hezode C; Hindman SJ; Hofer H; Husa P; Idilman R; Kaberg M; Kaita KDE; Kautz A; Kaymakoglu S; Krajden M; Krarup H; Laleman W; Lavanchy D; Lazaro P; Marinho RT; Marotta P; Mauss S; Mendes Correa MC; Moreno C; Muellhaupt B; Myers RP; Nemecek V; Ovrehus ALH; Parkes J; Peltekian KM; Ramji A; Razavi H; Reis N; Roberts SK; Roudot-Thoraval F; Ryder SD; Sarmento-Castro R; Sarrazin C; Semela D; Sherman M; Shiha GE; Sperl J; Starkel P; Stauber RE; Thompson AJ; Urbanek P; Van Damme P; van Thiel I; Vandijck D; Vogel W; Waked I; Weis N; Wiegand J; Yosry A; Zekry A; Negro F; Sievert W; Gower E
Article: JOURNAL OF VIRAL HEPATITIS. 2014;21:34-59
The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm
Razavi H; Waked I; Sarrazin C; Myers RP; Idilman R; Calinas F; Vogel W; Mendes Correa MC; Hezode C; Lazaro P; Akarca U; Aleman S; Balik I; Berg T; Bihl F; Bilodeau M; Blasco AJ; Brandao Mello CE; Bruggmann P; Buti M; Calleja JL; Cheinquer H; Christensen PB; Clausen M; Coelho HSM; Cramp ME; Dore GJ; Doss W; Duberg AS; El-Sayed MH; Ergor G; Esmat G; Falconer K; Felix J; Ferraz MLG; Ferreira PR; Frankova S; Garcia-Samaniego J; Gerstoft J; Giria JA; Goncales FLJ; Gower E; Gschwantler M; Guimaraes Pessoa M; Hindman SJ; Hofer H; Husa P; Kaberg M; Kaita KDE; Kautz A; Kaymakoglu S; Krajden M; Krarup H; Laleman W; Lavanchy D; Marinho RT; Marotta P; Mauss S; Moreno C; Murphy K; Negro F; Nemecek V; Ormeci N; Ovrehus ALH; Parkes J; Pasini K; Peltekian KM; Ramji A; Reis N; Roberts SK; Rosenberg WM; Roudot-Thoraval F; Ryder SD; Sarmento-Castro R; Semela D; Sherman M; Shiha GE; Sievert W; Sperl J; Starkel P; Stauber RE; Thompson AJ; Urbanek P; Van Damme P; van Thiel I; Van Vlierberghe H; Vandijck D; Wedemeyer H; Weis N; Wiegand J; Yosry A; Zekry A; Cornberg M; Muellhaupt B; Estes C
Article: JOURNAL OF VIRAL HEPATITIS. 2014;21:5-33
Historical epidemiology of hepatitis C virus (HCV) in selected countries
Bruggmann P; Berg T; Ovrehus ALH; Moreno C; Brandao Mello CE; Roudot-Thoraval F; Marinho RT; Sherman M; Ryder SD; Sperl J; Akarca U; Balik I; Bihl F; Bilodeau M; Blasco AJ; Buti M; Calinas F; Calleja JL; Cheinquer H; Christensen PB; Clausen M; Coelho HSM; Cornberg M; Cramp ME; Dore GJ; Doss W; Duberg AS; El-Sayed MH; Ergor G; Esmat G; Estes C; Falconer K; Felix J; Ferraz MLG; Ferreira PR; Frankova S; Garcia-Samaniego J; Gerstoft J; Giria JA; Goncales FLJ; Gower E; Gschwantler M; Guimaraes Pessoa M; Hezode C; Hofer H; Husa P; Idilman R; Kaberg M; Kaita KDE; Kautz A; Kaymakoglu S; Krajden M; Krarup H; Laleman W; Lavanchy D; Lazaro P; Marotta P; Mauss S; Mendes Correa MC; Muellhaupt B; Myers RP; Negro F; Nemecek V; Ormeci N; Parkes J; Peltekian KM; Ramji A; Razavi H; Reis N; Roberts SK; Rosenberg WM; Sarmento-Castro R; Sarrazin C; Semela D; Shiha GE; Sievert W; Starkel P; Stauber RE; Thompson AJ; Urbanek P; van Thiel I; Van Vlierberghe H; Vandijck D; Vogel W; Waked I; Wedemeyer H; Weis N; Wiegand J; Yosry A; Zekry A; Van Damme P; Aleman S; Hindman SJ
Article: CLINICAL INFECTIOUS DISEASES. 2013;57(2):230-236
A Risk for Hepatocellular Carcinoma Persists Long-term After Sustained Virologic Response in Patients With Hepatitis C-Associated Liver Cirrhosis
Aleman S; Rahbin N; Weiland O; Davidsdottir L; Hedenstierna M; Rose N; Verbaan H; Stal P; Carlsson T; Norrgren H; Ekbom A; Granath F; Hultcrantz R
Article: BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS. 2013;433(1):31-35
Non-structural 3 protein expression is associated with T cell protein tyrosine phosphatase and viral RNA levels in chronic hepatitis C patients
Rahbin N; Frelin L; Aleman S; Hultcrantz R; Sallberg M; Brenndorfer ED
Article: JOURNAL OF IMMUNOLOGY. 2012;189(9):4510-4519
TCR-Redirected Human T Cells Inhibit Hepatitis C Virus Replication: Hepatotoxic Potential Is Linked to Antigen Specificity and Functional Avidity
Pasetto A; Frelin L; Aleman S; Holmstrom F; Brass A; Ahlen G; Brenndorfer ED; Lohmann V; Bartenschlager R; Sallberg M; Bertoletti A; Chen M
Article: GUT. 2012;61(4):589-596
Hepatitis C virus non-structural 3/4A protein interferes with intrahepatic interferon-γ production
Brenndorfer ED; Brass A; Soderholm J; Frelin L; Aleman S; Bode JG; Sallberg M
Article: SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY. 2011;46(9):1118-1126
Health check-ups and family screening allow detection of hereditary hemochromatosis with less advanced liver fibrosis and survival comparable with the general population
Aleman S; Endalib S; Stal P; Loof L; Lindgren S; Sandberg-Gertzen H; Almer S; Olsson S; Danielsson A; Wallerstedt S; Hultcrantz R
Article: JOURNAL OF VIRAL HEPATITIS. 2011;18(2):106-118
The burden of hepatitis C in Sweden: a national study of inpatient care
Duberg A-S; Pettersson H; Aleman S; Blaxhult A; Daviosdottir L; Hultcrantz R; Back E; Ekdahl K; Montgomery SM
Article: SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY. 2010;45(7-8):944-952
Hepatocellular carcinoma in individuals with HBV infection or HBV-HCV co-infection in a low endemic country
Davidsdottir L; Duberg A-S; Torner A; Aleman S; Back E; Ekdahl K; Blaxhult A; Ekbom A; Hultcrantz R
Article: LAKARTIDNINGEN. 2009;106(14):1016-1019
[Fibrosis indexes reduce the need of liver biopsy in chronic hepatitis C].
Björklund J; Aleman S; Weiland O
Article: GUT. 2009;58(4):560-569
Cleavage of the IPS-1/Cardif/MAVS/VISA does not inhibit T cell-mediated elimination of hepatitis C virus non-structural 3/4A-expressing hepatocytes
Ahlen G; Derk E; Weiland M; Jiao J; Rahbin N; Aleman S; Peterson DL; Pokrovskaja K; Grander D; Frelin L; Sallberg M
Article: SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES. 2009;41(9):679-684
Hepatitis C infection among injection drug users in Stockholm Sweden: Prevalence and gender
Lidman C; Norden L; Kaberg M; Kall K; Franck J; Aleman S; Birk M
Article: JOURNAL OF VIRAL HEPATITIS. 2008;15(7):538-550
Cause of death in individuals with chronic HBV and/or HCV infection, a nationwide community-based register study
Duberg A-S; Torner A; Daviosdottir L; Aleman S; Blaxhult A; Svensson A; Hultcrantz R; Back E; Ekdahl K
Article: ACTA RADIOLOGICA. 2008;49(3):251-257
Detection and characterization of focal liver lesions with contrast-enhanced ultrasonography in patients with hepatitis C-induced liver cirrhosis
Rahbin N; Siosteen A-K; Elvin A; Blomqvist L; Hagen K; Hultcrantz R; Aleman S
Article: SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY. 2008;43(11):1378-1386
Pegylated interferon and ribavirin combination therapy for chronic hepatitis C virus infection in patients with Child-Pugh Class A liver cirrhosis
Syed E; Rahbin N; Weiland O; Carlsson T; Oksanen A; Birk M; Davidsdottir L; Hagen K; Hultcrantz R; Aleman S
Article: AIDS. 2004;18(5):817-819
Minor nef gene alterations after human HIV-DNA immunisation
Aleman S; Leitner T; Liu MA; Wahren B
Article: CLINICAL AND EXPERIMENTAL IMMUNOLOGY. 2003;106(1):35-39
Site-directed serology of HIV-1 subtype B infection: Relation between virus specific antibody levels and disease progression
Brostrom C; Sonnerborg A; Kim S; Sallberg M
Article: AIDS. 2002;16(7):1039-1044
Drug resistance at low viraemia in HIV-1-infected patients with antiretroviral combination therapy
Aleman S; Söderbärg K; Visco-Comandini U; Sitbon G; Sönnerborg A
Article: CLINICAL AND EXPERIMENTAL IMMUNOLOGY. 2002;127(3):486-494
Plasma levels of soluble CD27:: a simple marker to monitor immune activation during potent antiretroviral therapy in HIV-1-infected subjects
De Milito A; Aleman S; Marenzi R; Sönnerborg A; Fuchs D; Zazzi M; Chiodi F
Article: JOURNAL OF BIOLOGICAL REGULATORS AND HOMEOSTATIC AGENTS. 2001;15(3):299-303
Human immunodeficiency virus type 1 variability and long-term non-progression
Visco-Comandini U; Aleman S; Yun Z; Sönnerborg A
Article: HIV MEDICINE. 2000;1(4):205-211
Proviral HIV-1 dynamics and evolution in patients receiving efficient long-term antiretroviral combination therapy.
Birk M; Aleman S; Visco-Comandini U; Sönnerborg A
Article: AIDS RESEARCH AND HUMAN RETROVIRUSES. 2000;16(14):1379-1384
High plasma levels of soluble Fas in HIV type 1-infected subjects are not normalized during highly active antiretroviral therapy
De Milito A; Hejdeman B; Albert J; Aleman S; Sönnerborg A; Zazzi M; Chiodi F
Article: AIDS RESEARCH AND HUMAN RETROVIRUSES. 1999;15(14):1249-1254
Long-term effects of antiretroviral combination therapy on HIV type 1 DNA levels
Aleman S; Visco-Comandini U; Loré K; Sönnerborg A
Article: ANTIVIRAL THERAPY. 1999;4(2):109-115
Kinetics of β-chemokine levels during anti-HIV therapy
Aleman S; Pehrson P; Sonnerborg A
Article: CLINICAL AND VACCINE IMMUNOLOGY. 1998;5(4):463-466
Human immunodeficiency virus type 1 disease progression, CCR5 genotype, and specific immune responses
Visco-Comandini U; Hultgren C; Brostrom C; Birk M; Kim S; Sallberg M
Visa fler

Alla övriga publikationer

Conference publication: ZEITSCHRIFT FUR GASTROENTEROLOGIE. 2024;62(09):e649
Improvement in noninvasive tests (LSM, FIB-4, and APRI) is seen through 96 weeks of bulevirtide monotherapy in CHD regardless of virologic response
Castera L; Aleman S; Lampertico P; Bogomolov P; Manuilov D; An Q; Da BL; Flaherty J; Mercier R-C; Lau AH; Chee G; Stepanova T; Zeuzem S; Wedemeyer H; Bourliere M; Zoulim F; Asselah T; Brunetto MR
Conference publication: ZEITSCHRIFT FUR GASTROENTEROLOGIE. 2024;62(09):e565-e566
Results from an integrated analysis at week 96: continued treatment of early virologic non-responder or partial responders with bulevirtide monotherapy for chronic hepatitis D leads to improvement in virologic and biochemical responses
Lampertico P; Wedemeyer H; Brunetto MR; Bogomolov P; Stepanova T; Bourliere M; Fontaine H; Chee G; Manuilov D; An Q; Lau AH; Da BL; Flaherty J; Mercier R-C; Frenette C; Osinusi A; Gherlan GS; Streinu-Cercel A; Zeuzem S; Cornberg M; Roulot D; Zoulim F; Aleman S; Asselah T
Conference publication: 2024;:a259.2-a2a260
IDDF2024-ABS-0269 Results from an integrated analysis at week 96: continued treatment of early virologic non-responder or partial responders with bulevirtide monotherapy for chronic hepatitis d leads to improvement in virologic and biochemical responses
Yu J; Lampertico P; Wedemeyer H; Brunetto M; Bogomolov P; Stepanova T; Bourliere M; Fontaine H; Chee G; Manuilov D; An Q; Lau A; Da B; Flaherty J; Mercier R-C; Frenette C; Osinusi A; Gherlan G; Streinu-Cercel A; Zeuzem S; Cornberg M; Roulot D; Zoulim F; Aleman S; Asselah T
Conference publication: 2024;:a259.1-a2a259
IDDF2024-ABS-0267 Continued treatment of early nonresponders or partial virologic responders with bulevirtide monotherapy in patients with chronic hepatitis delta through week 96 leads to improvement in virologic and biochemical responses
Yu J; Lampertico P; Wedemeyer H; Brunetto M; Bogomolov P; Stepanova T; Ciesek S; Berger A; Manuilov D; An Q; Lau A; Da B; Flaherty J; Mercier R-C; Zeuzem S; Cornberg M; Buti M; Aleman S
Conference publication: 2024;:a258
IDDF2024-ABS-0266 Efficacy and safety at 96 weeks of bulevirtide 2mg or 10 mg monotherapy for chronic hepatitis D (CHD): results from an interim analysis of a phase 3 randomized study
Yu J; Wedemeyer H; Aleman S; Brunetto M; Blank A; Andreone P; Bogomolov P; Chulanov V; Mamonova N; Geyvandova N; Morozov V; Sagalova O; Stepanova T; Manuilov D; Mercier R-C; An Q; Flaherty J; Osinusi A; Lau A; Wiesch JSZ; Cornberg M; Zeuzem S; Lampertico P
Preprint: RESEARCH SQUARE. 2024
Identification of soluble biomarkers that associate with distinct manifestations of long COVID
Buggert M; Gao Y; Cai C; Adamo S; Biteus E; Kamal H; Dager L; Miners K; Llewellyn-Lacey S; Ladell K; Sabberwal P; Bentley K; Wu J; Akhirunnesa M; Jones S; Julin P; Lidman C; Stanton R; Davies H; Aleman S; Price D; Goepfert P; Deeks S; Peluso M
Preprint: RESEARCH SQUARE. 2024
No Increased Risk of Hepatitis B Virus Infection in Patients with Celiac Disease; A Population- Based Study
Jossen J; Lebwohl B; Söderling J; Duberg A-S; Aleman S; Sharma R; Hagström H; Green PH; Ludvigsson JF
Preprint: RESEARCH SQUARE. 2024
Exploring the interplay between antiretroviral therapy and the gut-oral microbiome axis in people living with HIV
Narayanan A; Kieri O; Vesterbacka J; Manoharan L; Chen P; Ghorbani M; Ljunggren H-G; Chen MS; Aleman S; Sönnerborg A; Ray S; Nowak P
Letter: HAEMATOLOGICA. 2024;109(2):646-651
Systemic and mucosal adaptive immunity to SARS-CoV-2 during the Omicron wave in patients with chronic lymphocytic leukemia
Ingelman-Sundberg HM; Blixt L; Wullimann D; Wu J; Gao Y; Healy K; Muschiol S; Bogdanovic G; Aberg M; Kjellander C; Grifoni A; Sette A; Aleman S; Chen P; Blennow O; Hansson L; Ljunggren H-G; Chen MS; Buggert M; Osterborg A
Conference publication: ZEITSCHRIFT FUR GASTROENTEROLOGIE. 2024;62(01):e49-e50
Efficacy and Safety at 96 weeks of Bulevirtide 2 mg or 10 mg Monotherapy for Chronic Hepatitis Delta: Results From an Interim Analysis of a Phase 3 Randomized Study
Wedemeyer H; Aleman S; Brunetto M; Blank A; Andreone P; Bogomolov P; Chulanov V; Mamonova N; Geyvandova N; Morozov V; Sagalova O; Stepanova T; Manuilov D; Mercier R-C; An Q; Flaherty JF; Osinusi A; Lau A; Wiesch JZS; Cornberg M; Zeuzem S; Lampertico P
Corrigendum: NATURE IMMUNOLOGY. 2023;24(10):1778
SARS-CoV-2 reservoir in post-acute sequelae of COVID-19 (PASC) (vol 24, pg 1616, 2023)
Proal AD; VanElzakker MB; Aleman S; Bach K; Boribong BP; Buggert M; Cherry S; Chertow DS; Davies HE; Dupont CL; Deeks SG; Eimer W; Ely EW; Fasano A; Freire M; Geng LN; Griffin DE; Henrich TJ; Iwasaki A; Izquierdo-Garcia D; Locci M; Mehandru S; Painter MM; Peluso MJ; Pretorius E; Price DA; Putrino D; Scheuermann RH; Tan GS; Tanzi RE; Vanbrocklin HF; Yonker LM; Wherry EJ
Review: NATURE IMMUNOLOGY. 2023;24(10):1616-1627
SARS-CoV-2 reservoir in post-acute sequelae of COVID-19 (PASC)
Proal AD; VanElzakker MB; Aleman S; Bach K; Boribong BP; Buggert M; Cherry S; Chertow DS; Davies HE; Dupont CL; Deeks SG; Eimer W; Ely EW; Fasano A; Freire M; Geng LN; Griffin DE; Henrich TJ; Iwasaki A; Izquierdo-Garcia D; Locci M; Mehandru S; Painter MM; Peluso MJ; Pretorius E; Price DA; Putrino D; Scheuermann RH; Tan GS; Tanzi RE; VanBrocklin HF; Yonker LM; Wherry EJ
Conference publication: GUT. 2023;72(SUPPL_3):a103-a104
EFFICACY AND SAFETY AT 96 WEEKS OF BULEVIRTIDE 2 MG OR 10 MG MONOTHERAPY FOR CHRONIC HEPATITIS DELTA: RESULTS FROM AN INTERIM ANALYSIS OF A PHASE 3 RANDOMIZED STUDY
Wedemeyer H; Aleman S; Brunetto M; Blank A; Andreone P; Bogomolov P; Chulanov V; Mamonova N; Geyvandova N; Morozov V; Sagalova O; Stepanova T; Manuilov D; Mercier R-C; An Q; Flaherty J; Osinusi A; Lau A; zur Wiesch JS; Cornberg M; Zeuzem S; Lampertico P
Conference publication: GUT. 2023;72(SUPPL_3):a101.2-a1a102
CONTINUED TREATMENT OF EARLY NONRESPONDER OR PARTIAL VIROLOGIC RESPONDERS WITH BULEVIRTIDE MONOTHERAPY IN PATIENTS WITH CHRONIC HEPATITIS DELTA (CHD) THROUGH WEEK 96 LEADS TO IMPROVEMENT IN VIROLOGIC AND BIOCHEMICAL RESPONSES
Lampertico P; Wedemeyer H; Brunetto M; Bogomolov P; Stepanova T; Ciesek S; Berger A; Manuilov D; An Q; Lau A; Da B; Flaherty J; Mercier R-C; Zeuzem S; Cornberg M; Buti M; Aleman S
Conference publication: ZEITSCHRIFT FUR GASTROENTEROLOGIE. 2023;61(08):e455-e456
Efficacy and safety of bulevirtide monotherapy given at 2-mg or 10-mg dose level once daily for treatment of chronic hepatitis delta: Week 48 primary endpoint results from a Phase 3 randomized, multicenter, parallel design study
Wedemeyer H; Deterding K; Aleman S; Brunetto M; Blank A; Andreone P; Bogomolov P; Chulanov V; Mamonova N; Geyvandova N; Morozov V; Sagalova O; Stepanova T; Manuilov D; Suri V; An Q; Flaherty J; Osinusi A; Wiesch JSZ; Cornberg M; Zeuzem S; Lampertico P
Review: LIVER INTERNATIONAL. 2023;43:5-21
Natural history of untreated HDV patients: Always a progressive disease?
Kamal H; Aleman S
Conference publication: JOURNAL OF HEPATOLOGY. 2023;78:S1101-S1102
Liver stiffness measurement as a non-invasive method for the diagnosis of liver cirrhosis in patients with chronic hepatitis D virus infection
Sandmann L; Port K; Lampertico P; Aleman S; Cornberg M; Maasoumy B; Wedemeyer H; Deterding K
Preprint: RESEARCH SQUARE. 2023
Booster mRNA vaccination post-SARS-CoV-2 infection enhances functional qualities of T cell immunity
Buggert M; Cai C; Gao Y; Ballesteros OR; Hansson L; Österborg A; Sandberg J; Ljunggren H-G; Björkström N; Strålin K; Qin C; Grifoni A; Weiskopf D; Wherry E; Sette A; Aleman S
Corrigendum: JOURNAL OF INFECTIOUS DISEASES. 2023;227(4):603
Persisting Salivary IgG Against SARS-CoV-2 at 9 Months After Mild COVID-19: A Complementary Approach to Population Surveys (vol 224, pg 407, 2021)
Alkharaan H; Bayati S; Hellstrom C; Aleman S; Olsson A; Lindahl K; Bogdanovic G; Healy K; Tsilingaridis G; De Palma P; Hober S; Manberg A; Nilsson P; Pin E; Sallberg Chen M
Preprint: RESEARCH SQUARE. 2023
Impact of the gut microbiome on immunological responses to COVID-19 vaccination in healthy controls and people living with HIV
Ray S; Narayanan A; Vesterbacka J; Blennow O; Chen P; Gao Y; Gabarrini G; Ljunggren H-G; Buggert M; Manoharan L; Chen M; Aleman S; Sönnerborg A; Nowak P
Preprint: RESEARCH SQUARE. 2023
Systemic and mucosal adaptive immunity to SARS-CoV-2 during the Omicron wave in patients with chronic lymphocytic leukemia
Ingelman-Sundberg H; Blixt L; Wullimann D; Wu J; Gao Y; Healy K; Muschiol S; Bogdanovic G; Åberg M; Kjellander C; Grifoni A; Sette A; Aleman S; Chen P; Blennow O; Hansson L; Ljunggren H-G; Chen MS; Buggert M; Österborg A
Conference publication: JOURNAL OF HEPATOLOGY. 2023;78:S57-S58
Efficacy and safety at 96 weeks of bulevirtide 2 mg or 10 mg monotherapy for chronic hepatitis D: results from an interim analysis of a phase 3 randomized study
Wedemeyer H; Aleman S; Brunetto M; Blank A; Andreone P; Bogomolov P; Chulanov V; Mamonova N; Geyvandova N; Viacheslav M; Sagalova O; Stepanova T; Manuilov D; Mercier R-C; An Q; Flaherty JF; Osinusi A; Lau A; Wiesch JSZ; Cornberg M; Zeuzem S; Lampertico P
Conference publication: JOURNAL OF HEPATOLOGY. 2023;78:S34
Treatment with siRNA JNJ-73763989 plus nucleos (t)ide analogue (NA) decreases HBsAg and HDV RNA levels in patients with chronic hepatitis D (CHD): part 1 of the REEF-D study
Wedemeyer H; Gane EJ; Agarwal K; Tabak F; Forns X; Akarca U; Viacheslav M; Aleman S; Buti M; Yilmaz G; Lampertico P; Niewczas J; Jerzorwski J; Kakuda T; Benoot I; Pehlivanov N; Lenz O; Biermer M
Conference publication: JOURNAL OF HEPATOLOGY. 2023;78:S1150-S1151
The Nuc-Stop study: an open-label, randomized trial of different re-start strategies after treatment withdrawal in HBeAg negative chronic hepatitis B patients
Johannessen A; Reikvam DH; Aleman S; Berhe N; Weis N; Desalegn H; Stenstad T; Heggelund L; Samuelsen E; Lindahl K; Winckelmann A; Karlsen LN; Brugger-Synnes P; Simonsen HE; Svendsen J; Holmberg M; Dalgard O
Conference publication: JOURNAL OF HEPATOLOGY. 2023;78:S10
Week 48 results of the phase 3 D-LIVR study, a randomized double-blind, placebo-controlled trial evaluating the safety and efficacy of Lonafarnib-boosted with Ritonavir with or without Peginterferon Alfa in patients with chronic hepatitis delta
Etzion O; Hamid SS; Asselah T; Gherlan GS; Turcanu A; Petrivna T; Weissfeld L; Choong I; Hislop C; Apelian D; Buti M; Gheorghe L; Iliescu EL; Voronkova N; Barsukova N; Aleman S; Feld JJ; Reau NS; Brunetto M; Lampertico P; Heller T; Koh C; Yurdaydin C; Glenn J
Conference publication: JOURNAL OF HEPATOLOGY. 2023;78:S113-S114
Continued treatment of early non-responder or partial virologic responders with bulevirtide monotherapy in patients with chronic hepatitis D through week 96 leads to improvement in virologic and biochemical responses
Lampertico P; Wedemeyer H; Brunetto M; Bogomolov P; Stepanova T; Ciesek S; Berger A; Manuilov D; An Q; Lau A; Da B; Flaherty JF; Mercier R-C; Zeuzem S; Cornberg M; Buti M; Aleman S
Conference publication: JOURNAL OF HEPATOLOGY. 2023;78:S1091-S1093
Relationship of hepatitis D viral load, ALT levels, and liver stiffness in untreated patients with chronic hepatitis D
Aleman S; Lampertico P; Brunetto M; Bogomolov P; Chulanov V; Mamonova N; Stepanova T; Manuilov D; An Q; Ben D; Flaherty JF; Mercier R-C; Lau A; Zeuzem S; Cornberg M; Wedemeyer H
Conference publication: AMERICAN JOURNAL OF GASTROENTEROLOGY. 2023;118(10):S1214
Elevations in Total Serum Bile Acids During Bulevirtide Treatment Show No Association With Adverse Events of Interest in Patients With Chronic Hepatitis Delta: An Integrated Safety Analysis of 48Week Data
Lampertico P; Aleman S; Asselah T; Streinu-Cercel A; Bogomolov P; Morozov V; Stepanova T; Lazar S; Bacic A; Manuilov D; Mercier R-C; Flaherty JF; Suri V; Ye L; Tseng S; Christian-Cox F; Brunetto M; Wedemeyer H
Conference publication: HEPATOLOGY. 2023;78:S398-S399
NO DETECTABLE RESISTANCE TO BULEVIRTIDE MONOTHERAPY THROUGH 96 WEEKS TREATMENT IN PATIENTS WITH CHRONIC HEPATITIS D
Aleman S; Liu Y; Xu S; Chang S; Martin R; Aeschbacher T; May L; Manhas S; Han D; Yazdi T; Martinez C; Ho PY; Richards C; Marceau C; Manuilov D; Flaherty JF; Maiorova E; Mo H; Wedemeyer H; Lampertico P
Conference publication: HEPATOLOGY. 2023;78:S586-S588
RELATIONSHIP BETWEEN ALT NORMALIZATION RATES AND DIFFERENT VIROLOGIC RESPONSE CRITERIA IN CHRONIC HDV PATIENTS TREATED WITH BULEVIRTIDE MONOTHERAPY
Lampertico P; Aleman S; Bogomolov P; Stepanova T; Cornberg M; Ciesek S; Berger A; Manuilov D; An Q; Lau AH; Da BL; Flaherty JF; Mercier R-C; Liu Y; Brunetto MR; Zeuzem S; Wedemeyer H
Conference publication: HEPATOLOGY. 2023;78:S67-S70
CONTINUED TREATMENT OF EARLY VIROLOGIC NON-RESPONDER OR PARTIAL RESPONDERS WITH BULEVIRTIDE MONOTHERAPY FOR CHRONIC HEPATITIS D LEADS TO IMPROVEMENT IN VIROLOGIC AND BIOCHEMICAL RESPONSES: RESULTS FROM AN INTEGRATED ANALYSIS AT WEEK 96
Lampertico P; Wedemeyer H; Brunetto MR; Bogomolov P; Bourliere M; Fontaine H; Chee G; Manuilov D; Lau QAAH; Da BL; Flaherty JF; Mercier R-C; Frenette C; Osinusi AO; Sebastian Gherlan G; Zeuzem S; Cornberg M; Roulot DM; Zoulim F; Aleman S; Asselah T
Conference publication: HEPATOLOGY. 2023;78:S572-S574
IMPROVEMENT IN NONINVASIVE TESTS ( LSM, FIB-4, AND APRI) IS SEEN THROUGH 96 WEEKS OF BULEVIRTIDE MONOTHERAPY IN CHD REGARDLESS OF VIROLOGIC RESPONSE
Castera L; Aleman S; Lampertico P; Bogomolov P; Manuilov D; An Q; Da BL; Flaherty JF; Mercier R-C; Lau AH; Chee G; Stepanova T; Zeuzem S; Wedemeyer H; Bourliere M; Zoulim F; Asselah T; Brunetto MR
Conference publication: HEPATOLOGY. 2023;78:S557-S559
BASELINE CHARACTERISTICS OF HEPATITIS DELTA PATIENTS ENROLLED ACROSS PHASE 2 AND 3 STUDIES OF BULEVIRTIDE
Zoulim F; Asselah T; Lampertico P; Aleman S; Bourliere M; Bogomolov P; Morozov V; Stepanova T; Ye L; Da BL; Frenette C; Osinusi AO; Chee G; Manuilov D; Mercier R-C; Lau AH; Chulanov V; Mamonova N; Blank A; Zeuzem S; Cornberg M; Brunetto MR; Wedemeyer H
Conference publication: HEPATOLOGY. 2023;78:S564-S566
DEVELOPMENT OF ANTIDRUG ANTIBODIES ON BULEVIRTIDE MONOTHERAPY IN CHD DOES NOT IMPACT BULEVIRTIDE EFFICACY, SAFETY OR PHARMACOKINETICS
Lampertico P; Aleman S; Bogomolov P; Morozov V; Mamonova N; Manuilov D; Ye L; Da BL; Mercier R-C; Lau AH; Chee G; Mallalieu N; Kumar P; Stepanova T; Chulanov V; Zeuzem S; Wedemeyer H; Bourliere M; Zoulim F; Asselah T; Brunetto MR; Cornberg M; Blank A
Conference publication: JOURNAL OF IMMUNOLOGY. 2023;210(1)
Booster mRNA vaccination post-SARS-CoV-2 infection enhances functional qualities of T cell immunity
Cai C; Gao Y; Olsson A; Sette A; Wherry EJ; Aleman S; Buggert M
Conference publication: ZEITSCHRIFT FUR GASTROENTEROLOGIE. 2023;61(01):e45-e46
Efficacy and Safety of Bulevirtide Monotherapy Given at 2 mg or 10 mg Dose Level Once Daily for Treatment of Chronic Hepatitis Delta: Week 48 Primary Endpoint Results from a Phase 3 Randomized, Multicenter, Parallel Design Study
Wedemeyer H; Aleman S; Brunetto M; Blank A; Andreone P; Bogomolov P; Chulanov V; Mamonova N; Geyvandova N; Morozov V; Sagalova O; Stepanova T; Manuilov D; Suri V; An Q; Flaherty J; Osinusi A; Wiesch JZ; Cornberg M; Zeuzem S; Lampertico P
Conference publication: ZEITSCHRIFT FUR GASTROENTEROLOGIE. 2023;61(01):e47
Treatment with Bulevirtide Improves Patient-reported Outcomes in Patients with Chronic Hepatitis Delta: An Exploratory Analysis of a Phase 3 Trial at 48 Weeks
Buti M; Wedemeyer H; Aleman S; Chulanov V; Morozov V; Sagalova O; Stepanova T; Gish R; Lloyd A; Kaushik A; Suri V; Manuilov D; Osinusi A; Flaherty J; Lampertico P
Conference publication: JOURNAL OF IMMUNOLOGY. 2023;210(1)
Anamnestic expansion of Omicron-reactive CD8+T cells after booster SARS-CoV-2 mRNA vaccination across different immunocompromised states
Mueller TR; Sekine T; Trubach D; Niessl J; Olofsson A; Gao Y; Cai C; Nowak P; Blennow O; Hansson L; Mielke S; Bergman P; Ljunggren H-G; Karlsson AC; Saini SK; Aleman S; Buggert M
Conference publication: GASTROENTEROLOGY. 2023;164(6):S1037
RISK OF HEPATITIS B INFECTION IN PEOPLE WITH CELIAC DISEASE; A POPULATION-BASED STUDY
Jossen J; Lebwohl B; Soderling J; Duberg A-S; Aleman S; Sharma R; Hagstrom H; Green PH; Ludvigsson JF
Conference publication: JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (AUSTRALIA). 2023;38:69
Efficacy of bulevirtide as monotherapy for chronic hepatitis delta: Week 48 results from an integrated analysis
Freismuth A; Lampertico P; Aleman S; Blank A; Bogomolov P; Chulanov V; Mamonova N; Morozov V; Sagalova O; Stepanova T; Suri V; Manuilov D; Ye L; Flaherty JF; Osinusi AO; Cornberg M; Brunetto M; Wedemeyer H
Conference publication: JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (AUSTRALIA). 2023;38:70
Bulevirtide monotherapy is safe and well tolerated in patients with chronic hepatitis delta: An integrated safety analysis of 48-week data
Freismuth A; Asselah T; Lampertico P; Aleman S; Bourliere M; Streinu-Cercel A; Bogomolov P; Morozov V; Stepanova T; Lazar S; Suri V; Manuilov D; Mercier R-C; Tseng S; Ye L; Flaherty JF; Osinusi AO; Brunetto M; Wedemeyer H
Letter: HEPATOLOGY COMMUNICATIONS. 2022;6(12):3593-3594
Reply Comment on risk of HCC with chronic hepatitis B infection in Sweden
Duberg A-S; Lybeck C; Falt A; Montgomery S; Aleman S
Letter: BLOOD COAGULATION AND FIBRINOLYSIS. 2022;33(5):285-287
Postacute elevation of D-dimer levels in severe acute respiratory syndrome coronavirus 2-positive nonhospitalized patients with mild symptoms
Folkman R; Kamal H; Ahl M; Szum A; Magnusson M; Aleman S
Letter: HAEMATOLOGICA. 2022;107(4):1000-1003
T-cell immune responses following vaccination with mRNA BNT162b2 against SARS-CoV-2 in patients with chronic lymphocytic leukemia: results from a prospective open-label clinical trial
Blixt L; Wullimann D; Aleman S; Lundin J; Chen P; Gao Y; Cuapio A; Akber M; Lange J; Rivera-Ballesteros O; Buggert M; Ljunggren H-G; Hansson L; Osterborg A
Letter: AIDS. 2022;36(3):479-481
High seroconversion rate after vaccination with mRNA BNT162b2 vaccine against SARS-CoV-2 among people with HIV - but HIV viremia matters?
Xu X; Vesterbacka J; Aleman S; Nowak P
Preprint: RESEARCH SQUARE. 2022
Novel universal SARS-CoV DNA vaccine inducing neutralizing antibodies to huCoV-19/WH01, Beta, Delta and Omicron variants and T cells to Bat-CoV
Appelberg S; Ahlen G; Nikoyan N; Yan J; Weber S; Larsson O; Höglund U; Aleman S; Weber F; Perlhamre E; Apro J; Gidlund E-K; Tuvesson O; Cadossi M; Salati S; Tegel H; Hober S; Frelin L; mirazimi A; Sallberg M
Preprint: RESEARCH SQUARE. 2022
Ancestral SARS-CoV-2-specific T cells cross-recognize Omicron (B.1.1.529)
Gao Y; Cai C; Grifoni A; Müller T; Niessl J; Olofsson A; Humbert M; Hansson L; Österborg A; Bergman P; Chen P; Olsson A; Sandberg J; Weiskopf D; Price D; Ljunggren H-G; Karlsson A; Sette A; Aleman S; Buggert M
Conference publication: JOURNAL OF HEPATOLOGY. 2022;77:S30
Liver stiffness predicts incident severe liver disease in patients with chronic liver disease
Hegmar H; Wester A; Aleman S; Backman J; Degerman E; Ekvall H; Lund K; Lundgren A; Nasr P; Shahnavaz A; Vessby J; Westin J; Onnerhag K; Hagstrom H
Conference publication: AMERICAN JOURNAL OF GASTROENTEROLOGY. 2022;117(10):S858-S859
Bulevirtide Monotherapy at Low and High Dose in Patients With Chronic Hepatitis Delta: 24-Week Interim Data of the Phase 3 MYR301 Study
Lee S; Wedemeyer H; Aleman S; Brunetto M; Blank A; Andreone P; Bogomolov P; Chulanov V; Mamonova N; Geyvandova N; Morozov V; Sagalova O; Stepanova T; Manuilov D; Suri V; An Q; Flaherty JF; Osinusi A; zur Wiesch JS; Cornberg M; Zeuzem S; Lampertico P
Conference publication: HEPATOLOGY. 2022;76:S224-S225
BULEVIRTIDE IMPROVES HEALTH RELATED QUALITY LIFE MEASURED BY EQ-5D VAS IN PATIENTS WITH CHRONIC HEPATITIS DELTA: AN EXPLORATORY ANALYSIS OF A PHASE 3 TRIAL AT 48 WEEKS
Buti M; Wedemeyer H; Aleman S; Chulanov V; Morozov V; Sagalova O; Stepanova T; Gish RG; Lloyd A; Kaushik AM; Suri V; Manuilov D; Osinusi AO; Flaherty JF; Pandey S; Singh B; Lampertico P
Conference publication: HEPATOLOGY. 2022;76:S220-S221
BULEVIRTIDE MONOTHERAPY IS SAFE AND WELL TOLERATED IN PATIENTS WITH CHRONIC HEPATITIS D (CHD): AN INTEGRATED SAFETY ANALYSIS OF 48-WEEK DATA
Asselah T; Lampertico P; Aleman S; Bourliere M; Streinu-Cercel A; Bogomolov P; Morozov V; Stepanova T; Lazar S; Suri V; Manuilov D; Mercier R-C; Tseng S; Ye L; Flaherty JF; Osinusi AO; Brunetto M; Wedemeyer H
Conference publication: HEPATOLOGY. 2022;76:S228-S230
EFFICACY OF BULEVIRTIDE AS MONOTHERAPY FOR CHRONIC HEPATITIS D (CHD): WEEK 48 RESULTS FROM AN INTEGRATED ANALYSIS
Lampertico P; Aleman S; Blank A; Bogomolov P; Chulanov V; Mamonova N; Morozov V; Sagalova O; Stepanova T; Suri V; Manuilov D; Ye L; Flaherty JF; Osinusi AO; Cornberg M; Brunetto M; Wedemeyer H
Conference publication: JOURNAL OF HEPATOLOGY. 2022;77:S103
Treatment with bulevirtide improves patient-reported outcomes in patients with chronic hepatitis delta: An exploratory analysis of a Phase 3 trial at 48 weeks
Buti M; Wedemeyer H; Aleman S; Chulanov V; Viacheslav M; Sagalova O; Stepanova T; Gish RG; Lloyd A; Kaushik A; Suri V; Manuilov D; Osinusi A; Flaherty JF; Lampertico P
Conference publication: JOURNAL OF HEPATOLOGY. 2022;77:S4-S5
Efficacy and safety of bulevirtide monotherapy given at 2 mg or 10 mg dose level once daily for treatment of chronic hepatitis delta: week 48 primary end point results from a phase 3 randomized, multicenter, parallel design study
Wedemeyer H; Aleman S; Brunetto M; Blank A; Andreone P; Bogomolov P; Chulanov V; Mamonova N; Geyvandova N; Viacheslav M; Sagalova O; Stepanova T; Manuilov D; Suri V; An Q; Flaherty JF; Osinusi A; Zur Wiesch JS; Cornberg M; Zeuzem S; Lampertico P
Conference publication: JOURNAL OF HEPATOLOGY. 2022;77:S828
Integrated efficacy analysis of 24-week data from two phase 2 and one phase 3 clinical trials of bulevirtide monotherapy given at 2 mg or 10 mg dose level for treatment of chronic hepatitis delta
Lampertico P; Aleman S; Blank A; Bogomolov P; Chulanov V; Mamonova N; Viacheslav M; Sagalova O; Stepanova T; Suri V; Manuilov D; Ye L; Flaherty JF; Osinusi A; Cornberg M; Brunetto M; Wedemeyer H
Conference publication: JOURNAL OF HEPATOLOGY. 2022;77:S829
Integrated safety analysis of 24-week data from three phase 2 and one phase 3 clinical trials of bulevirtide monotherapy given at 2 mg and 10 mg dose level for treatment of chronic hepatitis delta
Lampertico P; Aleman S; Asselah T; Bourliere M; Streinu-Cercel A; Bogomolov P; Viacheslav M; Stepanova T; Lazar S; Suri V; Manuilov D; Ye L; Flaherty JF; Osinusi A; Brunetto M; Wedemeyer H
Conference publication: JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (AUSTRALIA). 2022;37:52-53
Bulevirtide monotherapy at low and high doses in patients with chronic hepatitis delta: 24-week interim data of the Phase 3 MYR301 study
Freismuth A; Wedemeyer H; Aleman S; Brunetto M; Black A; Andreone P; Bogomolov P; Chulanov V; Mamonova N; Geyvandova N; Morozov V; Sagalova O; Stepanova T; Manuilov D; Suri V; An Q; Flaherty JF; Osinusi A; Zur Wiesch JS; Cornberg M; Zeuzem S; Lampertico P
Preprint: MEDRXIV. 2021
Appearance of IgG to SARS-CoV-2 in saliva effectively indicates seroconversion in mRNA vaccinated immunocompromised individuals
Healy K; Pin E; Chen P; Söderdahl G; Nowak P; Mielke S; Hansson L; Bergman P; Smith E; Ljungman P; Valentini D; Blennow O; Österborg A; Gabarrini G; Al-Manei K; Alkharaan H; Sobkowiak MJ; Xu X; Akber M; Loré K; Hellström C; Muschiol S; Bogdanovic G; Buggert M; Ljunggren H-G; Hober S; Nilsson P; Aleman S; Sällberg Chen M
Review: JOURNAL OF VIRAL HEPATITIS. 2021;28(10):1431-1442
Risk of hepatocellular carcinoma in hepatitis B and D virus co-infected patients: A systematic review and meta-analysis of longitudinal studies
Kamal H; Fornes R; Simin J; Stal P; Duberg A-S; Brusselaers N; Aleman S
Preprint: MEDRXIV. 2021
Safety and efficacy of the mRNA BNT162b2 vaccine against SARS-CoV-2 in five groups of immunocompromised patients and healthy controls in a prospective open-label clinical trial
Bergman P; Blennow O; Hansson L; Mielke S; Nowak P; Chen P; Söderdahl G; Österborg A; Edvard Smith CI; Wullimann D; Vesterbacka J; Lindgren G; Blixt L; Friman G; Wahren-Borgström E; Nordlander A; Gomez AC; Akber M; Valentini D; Norlin A-C; Thalme A; Bogdanovic G; Muschiol S; Nilsson P; Hober S; Loré K; Chen MS; Buggert M; Ljunggren H-G; Ljungman P; Aleman S; the COVAXID-collaborator group (shown separately)
Letter: HEPATOLOGY. 2021;74(2):1127-1128
Letter to the Editor: Interferon Is Not an Optimal Treatment for Chronic Hepatitis Delta but Needs "Fair Treatment" by Us REPLY
Kamal H; Weiland O; Aleman S
Preprint: BIORXIV. 2021
Longitudinal characterization of humoral and cellular immunity in hospitalized COVID-19 patients reveal immune persistence up to 9 months after infection
Sandberg JT; Varnaitė R; Christ W; Chen P; Muvva J; Maleki K; García M; Dzidic M; Folkesson E; Skagerberg M; Ahlén G; Frelin L; Sällberg M; The Karolinska COVID-19 Study Group; Eriksson L; Rooyackers O; Sönnerborg A; Buggert M; Björkström N; Aleman S; Strålin K; Klingström J; Ljunggren H-G; Blom K; Gredmark-Russ S
Preprint: MEDRXIV. 2021
Persisting Salivary IgG against SARS-CoV-2 at 9 Months After Mild COVID-19: A Complementary Approach to Population Surveys
Alkharaan H; Bayati S; Hellström C; Olsson A; Lindahl K; Bogdanovic G; Aleman S; Tsilingaridis G; De Palma P; Hober S; Månberg A; Nilsson P; Pin E; Sällberg Chen M
Preprint: MEDRXIV. 2021
High-dimensional profiling reveals phenotypic heterogeneity and disease-specific alterations of granulocytes in COVID-19
Lourda M; Dzidic M; Hertwig L; Bergsten H; Medina LP; Kvedaraite E; Chen P; Muvva J; Gorin J-B; Cornillet M; Emgård J; Moll K; García M; Maleki K; Klingström J; Michaëlsson J; Flodström-Tullberg M; Brighenti S; Buggert M; Mjösberg J; Malmberg K-J; Sandberg J; Henter J-I; Folkesson E; Gredmark-Russ S; Sönnerborg A; Eriksson L; Rooyackers O; Aleman S; Strålin K; Ljunggren H-G; Björkström N; Svensson M; Ponzetta A; Norrby-Teglund A; Chambers B; the Karolinska KI/K COVID-19 Study Group
Conference publication: HEPATOLOGY. 2021;74:413A-414A
TREATMENT WITH BULEVIRTIDE IMPROVES PATIENT REPORTED OUTCOMES IN PATIENTS WITH CHRONIC HEPATITIS DELTA (CHD): AN INTERIM EXPLORATORY ANALYSIS AT WEEK 24
Wedemeyer H; Aleman S; Chulanov V; Hilgard G; Antonova J; Kaushik AM; Lloyd A; Manuilov D; Suri V; Tran TT; Osinusi AO; Lampertico P; Morozov V; Sagalova O; Stepanova T; Buti M
Conference publication: JOURNAL OF HEPATOLOGY. 2021;75:S294-S295
Bulevirtide monotherapy at low and high dose in patients with chronic hepatitis delta: 24 weeks interim data of the phase 3 MYR301 study
Wedemeyer H; Aleman S; Andreone P; Blank A; Brunetto M; Bogomolov P; Chulanov V; Geyvandova N; Hilgard G; Mamonova N; Merle U; Viacheslav M; Sagalova O; Stepanova T; zur Wiesch JS; Zotov S; Zeuzem S; Lampertico P
Conference publication: HEPATOLOGY. 2021;74:574A
REAL-WORLD EFFECTIVENESS AND FACTORS ASSOCIATED WITH SVR12 IN A DIVERSE POPULATION OF HCV INFECTED PERSONS FROM FOUR LARGE EUROPEAN COHORTS
Peters L; Reekie J; Aleman S; Zazzi M; Abutidze A; Sonnerborg A; Rossetti B; Chkhartishvili N
Preprint: SSRN. 2021
Appearance of IgG to SARS-CoV-2 in Saliva Effectively Indicates Seroconversion in mRNA Vaccinated Immunocompromised Individuals
Healy K; Pin E; Chen P; Soderdahl G; Nowak P; Mielke S; Hansson L; Bergman P; Smith E; Ljungman P; Valentini D; Blennow O; Österborg A; Gabarrini G; Al-Manei K; Alkharaan H; Sobkowiak MJ; Xu X; Akber M; Lore K; Hellstrom C; Muschiol S; Bogdanovic G; Buggert M; Ljunggren H-G; Hober S; Nilsson P; Aleman S; Chen MS
Preprint: MEDRXIV. 2020
Innate lymphoid cell composition associates with COVID-19 disease severity
García M; Kokkinou E; García AC; Parrot T; Palma Medina L; Maleki K; Christ W; Varnaitė R; Filipovic I; Ljunggren H-G; Björkström N; Folkesson E; Rooyackers O; Eriksson L; Sönnerborg A; Aleman S; Strålin K; Gredmark-Russ S; Klingström J; Mjösberg J; the Karolinska KI/K COVID-19 Study Group
Preprint: MEDRXIV. 2020
MAIT cell activation and dynamics associated with COVID-19 disease severity and outcome
Parrot T; Gorin J-B; Ponzetta A; Maleki K; Kammann T; Emgârd J; Perez-Potti A; Sekine T; Rivera-Ballesteros O; the Karolinska COVID-19 Study Group; Folkesson E; Rooyackers O; Eriksson L; Norrby-Teglund A; Ljunggren H-G; Björkström N; Aleman S; Buggert M; Klingström J; Strålin K; Sandberg J
Preprint: MEDRXIV. 2020
Perturbations in the mononuclear phagocyte landscape associated with COVID-19 disease severity
Kvedaraite E; Hertwig L; Sinha I; Ponzetta A; Myrberg IH; Lourda M; Dzidic M; Akber M; Klingström J; Folkesson E; Muvva JR; Chen P; Brighenti S; Norrby-Teglund A; Eriksson L; Rooyackers O; Aleman S; Strålin K; Ljunggren H-G; Ginhoux F; Björkström N; Henter J-I; Svensson M; Karolinska COVID-19 Study Group
Preprint: MEDRXIV. 2020
Probabilistic approaches for classifying highly variable anti-SARS-CoV-2 antibody responses
Dopico X; Hanke L; Sheward D; Muschiol S; Aleman S; Grinberg N; Adori M; Christian M; Vidakovics LP; Kim C; Khoenkhoen S; Pushparaj P; Morro AM; Mandolesi M; Ahl M; Forsell M; Coquet J; Corcoran M; Rorbach J; Dillner J; Bogdanovic G; McInerney G; Allander T; Murrell B; Wallace C; Albert J; Karlsson Hedestam G
Preprint: MEDRXIV. 2020
Natural killer cell activation related to clinical outcome of COVID-19
Maucourant C; Filipovic I; Ponzetta A; Aleman S; Cornillet M; Hertwig L; Strunz B; Lentini A; Reinius B; Brownlie D; Gomez AC; Ask EH; Hull R; Haroun-Izquierdo A; Schaffer M; Klingström J; Folkesson E; Buggert M; Sandberg J; Eriksson L; Rooyackers O; Ljunggren H-G; Malmberg K-J; Michaëlsson J; Marquardt N; Hammer Q; Strålin K; Björkström N; Karolinska COVID-19 Study Group
Preprint: BIORXIV. 2020
Robust T cell immunity in convalescent individuals with asymptomatic or mild COVID-19
Sekine T; Perez-Potti A; Rivera-Ballesteros O; Strålin K; Gorin J-B; Olsson A; Llewellyn-Lacey S; Kamal H; Bogdanovic G; Muschiol S; Wullimann D; Kammann T; Emgård J; Parrot T; Folkesson E; Rooyackers O; Eriksson L; Sönnerborg A; Allander T; Albert J; Nielsen M; Klingström J; Gredmark-Russ S; Björkström N; Sandberg J; Price D; Ljunggren H-G; Aleman S; Buggert M; Karolinska COVID-19 Study Group
Review: CELLS. 2020;9(6):E1471-1471
Chronic Viral Liver Diseases: Approaching the Liver Using T Cell Receptor-Mediated Gene Technologies
Healy K; Pasetto A; Sobkowiak MJ; Soon CF; Cornberg M; Aleman S; Chen MS
Review: INFECTIOUS DISEASES. 2020;52(1):1-22
Management of hepatitis B virus infection, updated Swedish guidelines
Westin J; Aleman S; Castedal M; Duberg A-S; Eilard A; Fischlere B; Kampmann C; Lindahl K; Lindh M; Norkrans G; Stenmark S; Weiland O; Wejstal R
Conference publication: JOURNAL OF HEPATOLOGY. 2020;73:S379
Risk of hepatocellular carcinoma in hepatitis D co-infected patients compared to hepatitis B mono-infected patients: a systematic review and meta-analysis
Kamal H; Romina F; Johanna S; Brusselaers N; Aleman S
Preprint: BIORXIV. 2019
Plasma FABP4 is associated with liver disease recovery during treatment-induced clearance of chronic HCV infection
Gorin J-B; Malone DFG; Strunz B; Carlsson T; Aleman S; Björkström NK; Falconer K; Sandberg JK
Conference publication: JOURNAL OF HEPATOLOGY. 2019;70(1):E333-E334
The consensus hepatitis C cascade of care: Methodology and initial findings from three countries
Safreed-Harmon K; Blach S; Aleman S; Kielland KB; Bollerup S; Cooke G; Dalgard O; Dillon J; Dore G; Du Berg A-S; Grebely J; Midgard H; Porter K; Razavi H; Tyndall M; Weis N; Lazarus J
Conference publication: HEPATOLOGY. 2019;70:366A
ELEVATED RISK FOR LIVER RELATED MORTALITY IN CHRONIC HEPATITIS C PATIENTS BOTH WITH OR WITHOUT ILLICIT SUBSTANCE USE DISORDER: A NATION-WIDE REGISTER STUDY
Soderholm J; Larsson SB; Jerkeman A; Nystedt A; Duberg A-S; Kovamees J; Ydreborg M; Aleman S; Busch K; Blome MA; Weiland OR; Kaberg M
Conference publication: GASTROENTEROLOGY. 2019;156(6):S1200
ASPIRIN USE IS ASSOCIATED WITH REDUCED RISK FOR INCIDENT HEPATOCELLULAR CARCINOMA IN PATIENTS WITH CHRONIC VIRAL HEPATITIS: RESULTS FROM A NATIONWIDE POPULATION
Simon TG; Duberg A-S; Aleman S; Chung RT; Ludvigsson JF
Review: INFECTIOUS DISEASES. 2018;50(8):569-583
Treatment of hepatitis C virus infection for adults and children: updated Swedish consensus guidelines 2017
Lagging M; Wejstal R; Duberg A-S; Aleman S; Weiland O; Westin J
Meeting abstract: JOURNAL OF HEPATOLOGY. 2018;68:S367
Hepatitis C treatment in prisons through a nurse-led program with telemedicine
Olsson A; Roos K; Larsen S; Lindahl K; Gahrton C; Oksanen A; Ohrn F; Aleman S; Said K
Conference publication: JOURNAL OF HEPATOLOGY. 2018;68:S488
The incidence of hepatocellular carcinoma in hepatitis B virus infected persons of different origins, living in Sweden
Duberg A-S; Lybeck C; Falt A; Wedemeyer H; Montgomery S; Aleman S
Conference publication: JOURNAL OF HEPATOLOGY. 2018;68:S263-S264
A national study of risk for non-liver cancer in people with hepatitis C treated with direct acting antivirals or an interferon-based regimen
Lybeck C; Bruce D; Montgomery S; Aleman S; Duberg A-S
Conference publication: HEPATOLOGY. 2018;68:1190A-1191A
Long-Term Liver-Related Outcomes in Hepatitis B and D Co-Infected Patients in Sweden
Kamal H; Falconer K; Westman G; Duberg A-S; Weiland ORHJ; Wejstal R; Carlssson T; Kampmann C; Bjoerkman P; Nystedt A; Cardell K; Svensson S; Stenmark S; Wedemeyer H; Aleman S
Conference publication: HEPATOLOGY. 2018;68:59A-60A
Lipophilic Statins and Risk of Hepatocellular Carcinoma and Mortality: A Prospective, Nationwide Population with Chronic Viral Hepatitis
Simon TG; Duberg A-S; Aleman S; Hagstrom H; Chung RT; Ludvigsson JF
Review: INFECTIOUS DISEASES. 2017;49(8):561-575
Treatment of hepatitis C virus infection: updated Swedish Guidelines 2016
Lagging M; Wejstal R; Norkrans G; Karlstrom O; Aleman S; Weiland O; Castedal M; Westin J
Conference publication: JOURNAL OF IMMUNOLOGY. 2017;198(1)
MAIT cells in the human oral mucosa are activated and perforin^low
Sobkowiak M; Davanian H; Tjernlund A; Gibbs A; Nayak S; Leeansyah E; Dias J; Heymann R; Kruger-Weiner C; Aleman S; Moll M; Sallberg-Chen M; Sandberg JK
Meeting abstract: JOURNAL OF HEPATOLOGY. 2017;66(1):S493-S494
Long-term fibrosis improvement after sustained virologic response in patients with chronic hepatitis C and advanced fibrosis or cirrhosis - pre-treatment cirrhosis, older age and high body mass index increases the risk for persisting fibrosis
Hedenstierna M; Nangarhari A; Weiland O; Aleman S
Review: INFECTIOUS DISEASES. 2016;48(4):251-261
Treatment of hepatitis C virus infection for adults and children: Updated Swedish consensus recommendations
Lagging M; Wejstal R; Norkrans G; Karlstrom O; Aleman S; Weiland O; Castedal M; Josephson F
Editorial comment: HEPATOLOGY, MEDICINE AND POLICY. 2016;1:11
The hurdle with remaining risk for hepatocellular carcinoma in cirrhotic patients after a hepatitis C cure.
Aleman S
Meeting abstract: JOURNAL OF HEPATOLOGY. 2016;64:S620
THE PRESENCE OF DIABETES MELLITUS IS A STRONG RISK FACTOR FOR HEPATOCELLULAR CARCINOMA IN HEPATITIS C INFECTED PATIENTS WITH ADVANCED FIBROSIS OR CIRRHOSIS WHO HAVE ACHIEVED SUSTAINED VIROLOGICAL RESPONSE
Hedenstierna M; Nangarhari A; Weiland O; Aleman S
Meeting abstract: JOURNAL OF HEPATOLOGY. 2014;60(1):S325
ANALYSIS OF HCV MARKERS AND IMMUNE RESPONSES 5-20 YEARS AFTER SUCCESSFUL HCV THERAPY SUGGESTS THAT MOST PATIENTS ARE CURED
Brenndoerfer ED; Hedenstierna M; Bankwitz D; Behrendt P; Brass A; Uhnoo I; Aleman S; Fryden A; Norkrans G; Eilard A; Glaumann H; Cardell K; Pietschmann T; Weiland O; Sallberg M
Review: ARCHIVUM IMMUNOLOGIAE ET THERAPIAE EXPERIMENTALIS. 2014;62(1):23-30
Functional Attributes of Responding T Cells in HCV Infection: The Recent Advances in Engineering Functional Antiviral T Cells
Pasetto A; Aleman S; Chen M
Conference publication: HEPATOLOGY. 2014;60:1047A
The impact of different strategies to reduce the burden of chronic hepatitis C infection, using new direct acting antivirals in Sweden
Duberg A-S; Blach S; Falconer K; Kaberg M; Razavi H; Aleman S
Conference publication: HEPATOLOGY. 2013;58:280A
The risk for hepatocellular carcinoma among patients with chronic HCV infection and advanced hepatic fibrosis following sustained virological response
van der Meer AJ; Feld JJ; Hofer H; Almasio PL; Calvaruso V; Fernandez-Rodriguez CM; Aleman S; Ganne-Carrie N; D'Ambrosio R; Pol S; Trapero-Marugan M; Moreno-Otero R; Mallet V; Hultcrantz RW; Weiland O; Rutter K; Di Marco V; Alonso S; Bruno S; Colombo M; de Knegt RJ; Veldt BJ; Hansen BE; Janssen HL
Review: SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES. 2012;44(7):502-521
Treatment of hepatitis C virus infection in adults and children: Updated Swedish consensus recommendations
Lagging M; Duberg A-S; Wejstal R; Weiland O; Lindh M; Aleman S; Josephson F
Conference publication: HAEMOPHILIA. 2012;18:82-83
Long-term follow-up of hepatitis C in patients with bleeding disorders
Holmstrom M; Ihman J; Aleman S
Conference publication: HEPATOLOGY. 2011;54:839A-840A
DURABILITY OF SVR AND FIBROSIS IMPROVEMENT AFTER SOC TREATMENT FOR CHRONIC HCV-10 YEARS FOLLOW-UP
Hedenstierna M; Uhnoo I; Aleman S; Fryden A; Norkrans GP; Eilard A; Glaumann H; Cardell K; Weiland O
Conference publication: SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY. 2007;42:14
Hepatocellular cancer in Swedish hepatitis B patients and in hepatitis C co-infected patients
Daviosdottir L; Duberg A-S; Aleman S; Torner A; Back E; Ekdahl K; Blaxhult A; Hultcrantz R
Corrigendum: CLINICAL AND EXPERIMENTAL IMMUNOLOGY. 2003;134(1):167
Plasma levels of soluble CD27:: a simple marker to monitor immune activation during potent antiretroviral therapy in HIV-1-infected subjects (vol 127, pg 486, 2002)
De Milito A; Aleman S; Marenzi R; Sönnerborg A; Fuchs D; Zazzi M; Chiodi F
Thesis / dissertation: 2001
Studies on the efficacy of potent anti-HIV-1 therapy on virological and immunological factors
Aleman, Soo
Conference publication: AIDS. 1998;12:S70
Long term treatment effect on HIV-1 DNA levels
Aleman S; Comandini UV; Pehrsson PO; Moberg L; Sönnerborg A
Visa fler

Forskningsbidrag

Immunologic and virological correlates of long COVID: A bedside to bench approach
Swedish Research Council
1 December 2021 - 30 November 2025
Covid-19 vaccination in immunocompromised individuals: An interdisciplinary framework to gain clinical and mechanistic insight into durable immunity to SARS-CoV-2 infection
Swedish Research Council
1 June 2021 - 31 May 2025
Kartläggning av immunologiska faktorer i blod och lunga kopplat till långtids-Covid
Swedish Heart-Lung Foundation
1 January 2021 - 31 December 2021
Interdisciplinary framework on the role of adaptive cellular immunity in SARS-CoV-2 protection
Swedish Research Council
1 January 2021 - 31 December 2023
Clinical studies and analysis of hepatitis B, C and D liver cancer studies.
Swedish Cancer Society
1 January 2018
Clinical studies and analysis of hepatitis B, C and D liver cancer studies.
Swedish Cancer Society
1 January 2017

Anställningar

Anknuten till Forskning, Medicin, Huddinge, Karolinska Institutet, 2023-2026
Adjungerad Professor, Medicin, Huddinge, Karolinska Institutet, 2022-2026

Examina och utbildning

MEDICINE DOKTORSEXAMEN, Institutionen för laboratoriemedicin, Karolinska Institutet, 2001
LICENTIATEXAMEN, Institutionen för laboratoriemedicin, Karolinska Institutet, 1999
Läkarexamen, Karolinska Institutet, 1997

Artiklar

Alla övriga publikationer

Forskningsbidrag

Anställningar

Examina och utbildning

Nyheter från KI

Kalenderhändelser från KI